Jawed Fareed

Q: What Schools Are Affiliated With Jawed Fareed

Jawed Fareed is affiliated with the following schools: University of California, Berkeley, Albany College of Pharmacy and Health Sciences, University of California, Los Angeles, Marmara University, Stanford University, Loyola University Chicago, Trakya University

Jawed Fareed's AcademicInfluence.com Rankings

Jawed Fareed

Chemistry

#2346

World Rank

#3238

Historical Rank

Polymer Chemistry

#54

World Rank

#57

Historical Rank

Chemical Engineering

#209

World Rank

#223

Historical Rank

Organic Chemistry

#342

World Rank

#408

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Jawed Fareed's Degrees

PhD Chemistry University of California, Berkeley
Masters Chemical Engineering Stanford University
Bachelors Chemical Engineering Stanford University

Why Is Jawed Fareed Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jawed Fareed's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020) (1949)
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia (2001) (649)
Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period (2006) (390)
Prevention and treatment of venous thromboembolism - International Consensus Statement (Guidelines according to scientific evidence) (2006) (344)
Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. (2012) (315)
Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. (1998) (258)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation* (2013) (244)
STRUCTURAL STUDIES ON A BIOLOGICALLY ACTIVE HEXASACCHARIDE OBTAINED FROM HEPARIN (1981) (202)
Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. (2001) (195)
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research (2020) (194)
Prevention and treatment of venous thromboembolism--International Consensus Statement. (2013) (188)
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. (2019) (177)
Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. (2001) (143)
Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low-molecular-weight heparin derivatives. (1992) (143)
Pro-inflammatory biomakers in depression: Treatment with venlafaxine (2009) (137)
Patients With Cancer (2013) (132)
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine (2020) (131)
Prevention and Treatment of Venous Thromboembolism (2013) (125)
Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. (2000) (121)
Oligosaccharide mapping of low molecular weight heparins: structure and activity differences. (1990) (112)
Low-molecular-weight heparins: pharmacologic profile and product differentiation. (1998) (111)
Hemodynamic and fibrinolytic consequences of intermittent pneumatic compression: preliminary results. (1996) (108)
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent (2002) (105)
Role of neuropeptides in pathogenesis of reflex sympathetic dystrophy. (1998) (104)
ANTITHROMBOTIC ACTIVITY OF A SYNTHETIC HEPARIN PENTASACCHARIDE IN A RABBIT STASIS THROMBOSIS MODEL USING DIFFERENT THROMBOGENIC CHALLENGES (1987) (101)
Mechanical and histologic changes in canine vein grafts. (1988) (101)
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial (2021) (96)
Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. (1997) (94)
Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. (1999) (93)
Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies (2018) (92)
New Anticoagulants for the Cardiovascular Patient (1995) (91)
Isolation and characterization of human heparin. (1992) (89)
Plasma markers of endothelial dysfunction in pulmonary hypertension. (2001) (86)
Old versus new oral anticoagulants: focus on pharmacology. (2012) (80)
Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin (2003) (80)
Singlet oxygen inactivates fibrinogen, factor V, factor VIII, factor X, and platelet aggregation of human blood. (2000) (79)
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. (2005) (79)
Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. (1996) (78)
Circadian relationship of serum uric acid and nitric oxide. (2000) (78)
Erythropoietin-Induced Thrombosis as a Result of Increased Inflammation and Thrombin Activatable Fibrinolytic Inhibitor (2004) (77)
Low Levels of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Chronic Liver Disease (2001) (76)
Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. (1988) (76)
Synthetic Pentasaccharides Do Not Cause Platelet Activation by Antiheparin-Platelet Factor 4 Antibodies (1999) (75)
Are the available low-molecular-weight heparin preparations the same? (1996) (75)
Synthetic oligosaccharides can replace animal-sourced low–molecular weight heparins (2017) (74)
Survival of heparins, oral anticoagulants, and aspirin after the year 2010. (2008) (74)
Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. (2009) (74)
The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. (1988) (73)
Preparation and anticoagulant activity of the phosphosulfomannan PI-88. (2002) (69)
Does escitalopram reduce neurotoxicity in major depression? (2015) (68)
Thrombogenic potential of nonionic contrast media? (1990) (68)
The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low‐molecular‐weight heparin (1995) (67)
Viral Coagulopathy in Patients With COVID-19: Treatment and Care (2020) (67)
Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. (1998) (66)
Generic low-molecular-weight heparins: some practical considerations. (2004) (66)
Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. (2007) (65)
A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. (1985) (64)
Tissue factor antigen levels in various biological fluids (1995) (64)
Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. (1999) (64)
Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications--a review. (2000) (63)
Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. (2002) (61)
In Vitro Studies of the Interaction of Heparin, Low Molecular Weight Heparin and Heparinoids with Platelets (1989) (59)
Studies on the profibrinolytic actions of heparin and its fractions. (1985) (58)
Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death (2009) (57)
Effect of fast vs slow intralipid infusion on gas exchange, pulmonary hemodynamics, and prostaglandin metabolism. (1991) (56)
Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. (1989) (56)
LOW MOLECULAR WEIGHT HEPARIN PREVENTS THE PULMONARY HEMODYNAMIC AND PATHOMORPHOLOGIC EFFECTS OF ENDOTOXIN IN A PORCINE ACUTE LUNG INJURY MODEL (1998) (55)
Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. (1984) (55)
Product Individuality of Commercially Available Low-Molecular-Weight Heparins and Their Generic Versions: Therapeutic Implications (2006) (55)
Prevention of fatal pulmonary embolism and mortality in surgical patients (2005) (55)
Tissue factor and its natural inhibitor in pre-eclampsia and SGA (2008) (54)
Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. (1986) (54)
Superficial vein thrombosis: a consensus statement. (2012) (54)
The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. (2003) (53)
Leukocyte telomere length is associated with measures of subclinical atherosclerosis. (2010) (53)
Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. (1991) (53)
Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. (2003) (53)
TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. (1995) (52)
Day-Night Variations in Blood Levels of Nitric Oxide, T-TFPI, and E-Selectin (2001) (52)
A primate model for prolonged endotoxin shock. Blood-vascular reactions and effects of glucocorticoid treatment. (1978) (50)
Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis. (1999) (50)
Do blood constituents in varicose veins differ from the systemic blood constituents? (2015) (50)
Coagulation and fibrinolytic parameters in patients with pulmonary hypertension (1996) (49)
The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. (2002) (49)
Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease. (1996) (48)
Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. (2004) (48)
Protein C antigen deficiency and warfarin necrosis. (1986) (47)
Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. (1995) (47)
Biochemical and Pharmacologic Inequivalence of Low Molecular Weight Heparins (1989) (46)
Zika and Chikungunya Virus and Risk for Venous Thromboembolism (2019) (45)
Markers of Inflammation and Infection in Sepsis and Disseminated Intravascular Coagulation (2019) (45)
Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. (1985) (45)
Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations. (1989) (44)
Plasma Markers of Endothelial Dysfunction in Chronic Obstructive Pulmonary Disease (2001) (44)
Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. (1991) (44)
A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor (2008) (44)
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. (2002) (44)
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. (1999) (43)
Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. (2000) (43)
Laboratory monitoring of the clinical effects of low molecular weight heparins. (1991) (43)
Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. (2002) (43)
Neonatal and maternal platelets: Activation at time of birth (1988) (42)
Pharmacology of argatroban. (1999) (42)
Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. (1988) (41)
Human pharmacokinetics of low molecular weight heparins. (1999) (41)
Molecular profiling and weight determination of heparins and depolymerized heparins. (1995) (41)
The effect of molecular weight on the bioavailability of heparin. (1987) (41)
Anticoagulant and antithrombotic actions of a semisynthetic β-1,3-glucan sulfate (1995) (40)
Relationship between postsurgical fibrinolytic parameters and deep vein thrombosis in surgical patients treated with compression devices. (1988) (40)
Modulation of vasoconstriction by clopidogrel and ticlopidine. (1998) (40)
Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurements. (1982) (39)
Low molecular weight dermatan sulfate as an antithrombotic agent. Structure-activity relationship studies. (1994) (39)
A NEW ASSAY (1981) (39)
New perspectives in coagulation testing. (1980) (39)
Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity. (1988) (38)
Factor Xa inhibitors: today and beyond. (2003) (38)
The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity (2009) (38)
COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies (2021) (38)
Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment. (2018) (37)
Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. (2008) (37)
Anticoagulant and Antiprotease Profiles of a Novel Natural Heparinomimetic Mannopentaose Phosphate Sulfate (PI-88) (2001) (37)
Are Inflammatory Biomarkers Increased in Varicose Vein Blood? (2016) (37)
Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins (2016) (37)
Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. (1993) (36)
Preeclampsia is associated with low concentrations of protein Z (2007) (36)
An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent. (1991) (36)
High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor (2010) (36)
Differentiation of generic enoxaparins marketed in the United States by employing NMR and multivariate analysis. (2015) (35)
Molecular Markers of Hemostatic Activation: Applications in the Diagnosis of Thrombosis and Vascular and Thrombotic Disorders (1995) (35)
Low Molecular Weight Heparins: Differences and Similarities in Approved Preparations in the United States (1999) (35)
Low molecular weight glycosaminoglycan blockade of beta-amyloid induced neuropathology. (2002) (34)
Vascular Endothelial Growth Factor: a potential diagnostic biomarker for major depression. (2014) (34)
Recommendations on biosimilar low‐molecular‐weight heparins (2009) (34)
Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. (2002) (33)
Premature labor: a state of platelet activation? (2008) (33)
A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine. (1993) (32)
Heparin-induced Thrombocytopenia: Clinical Considerations of Alternative Anticoagulation with Various Glycosaminoglycans and Thrombin Inhibitors (1999) (32)
Antiphospholipid syndrome and pre-eclampsia. (2011) (32)
Transplantation of Lymph Node Fragments in a Rabbit Ear Lymphedema Model: A New Method for Restoring the Lymphatic Pathway (1998) (31)
Plasma protein Z concentrations in pregnant women with idiopathic intrauterine bleeding and in women with spontaneous preterm labor (2007) (31)
Newer avenues in the monitoring of antithrombotic therapy: the role of automation. (1983) (31)
Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders (2001) (30)
Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. (1990) (30)
Thrombin Anion‐binding Exosite Interactions with Heparin and Various Polyanions a (1989) (30)
Neonatal and maternal fibrinolysis: Activation at time of birth (1985) (30)
Update on the safety and bioequivalence of biosimilars – focus on enoxaparin (2013) (30)
Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development. (1998) (30)
Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin. (1995) (30)
Functional Heterogeneity of Antiheparin-Platelet Factor 4 Antibodies: Implications in the Pathogenesis of the HIT Syndrome (1999) (30)
Laboratory assays and duplex scanning outcomes after symptomatic deep vein thrombosis: preliminary results. (1996) (29)
A New Approach for Heparin Standardization: Combination of Scanning UV Spectroscopy, Nuclear Magnetic Resonance and Principal Component Analysis (2011) (29)
Tracheal and bronchial cartilaginous rings: warfarin sodium-induced calcification. (1992) (29)
Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. (2004) (29)
Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation (2019) (29)
Recombinant Full-length Tissue Factor Pathway Inhibitor (TFPI) Prevents Thrombus Formation and Rethrombosis after Lysis in a Rabbit Model of Jugular Vein Thrombosis (1996) (28)
Molecular markers of contrast media-induced adverse reactions. (1984) (28)
Anti-Xa and Anti-IIa Drugs Alter International Normalized Ratio Measurements: Potential Problems in the Monitoring of Oral Anticoagulants (2004) (28)
Authentication of animal origin of heparin and low molecular weight heparin including ovine, porcine and bovine species using 1D NMR spectroscopy and chemometric tools (2018) (28)
Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020 (2020) (28)
Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions. (1985) (28)
Pregnancy outcome in women with antiphospholipid antibodies: report on a retrospective study. (2008) (28)
Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites. (2014) (28)
Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model. (1991) (28)
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. (1983) (28)
Studies on a highly active anticoagulant fraction of high molecular weight isolated from porcine sodium heparin. (1982) (28)
Glucocorticoid and antibiotic effects on hepatic microcirculation and associated host responses in lethal gram-negative bacteremia. (1979) (27)
Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. (1994) (27)
Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. (2008) (27)
Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy (2020) (27)
Attenuation of Postmeal Metabolic Indices with Red Raspberries in Individuals at Risk for Diabetes: A Randomized Controlled Trial (2019) (27)
Global and molecular hemostatic markers in acute myeloid leukemia. (1990) (26)
Progressive Increase of Inflammatory Biomarkers in Chronic Kidney Disease and End-Stage Renal Disease (2013) (26)
Short- and long-acting synthetic pentasaccharides as antithrombotic agents (2005) (26)
Isolation and Characterization of Contaminants in Recalled Unfractionated Heparin and Low-Molecular-Weight Heparin (2009) (26)
Heparin oligosaccharides as potential therapeutic agents in senile dementia. (2007) (26)
Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin. (1989) (26)
Vascular endothelial growth factor: Potential predictor of treatment response in major depression (2017) (26)
In vitro evaluation of heparin fractions: old vs. new methods. (1986) (26)
Comparative studies on various assays for the laboratory evaluation of r-hirudin. (1991) (26)
Effects of nonionic contrast media (CM) on the components of coagulation and complement systems. (1982) (25)
Molecular markers of platelet activation. (1984) (25)
Antithrombin Agents: The New Class of Anticoagulant and Antithrombotic Drugs (1999) (25)
An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination (2021) (25)
Soluble P-Selectin in Human Plasma: Effect of Anticoagulant Matrix and its Levels in Patients With Cardiovascular Disorders (2000) (25)
State-of-the-Art-Review : The Antithrombotic Factor Singlet Oxygen/Light (1O2/hv) (2000) (25)
Thrombin Generation Mediators and Markers in Sepsis-Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin (2014) (25)
The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. (1992) (25)
Neonatal and maternal hemostasis: value of molecular markers in the assessment of hemostatic status. (1984) (25)
Tissue Factor Pathway Inhibitor Release Induced by Defibrotide and Heparins (2001) (25)
Antiplatelet Therapy Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist (2010) (25)
Further Removal of Factor V Related Antigen From Bovine Thrombin by Utilizing a Membrane-Filtration Step (2008) (25)
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict All-Cause Mortality in Acute Pulmonary Embolism (2019) (25)
Laboratory assays for the evaluation of recombinant hirudin. (1991) (25)
Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin‐induced thrombocytopenia with thrombosis (2010) (24)
A heparin-like compound isolated from a marine crab rich in glucuronic acid 2-O-sulfate presents low anticoagulant activity. (2013) (24)
Antithrombotic agents stimulate the synthesis and modify the sulfation pattern of a heparan sulfate proteoglycan from endothelial cells. (1994) (24)
Small-molecule direct antithrombins: argatroban. (2004) (24)
Low molecular weight heparins: are they different? (1998) (24)
In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole blood. (1991) (23)
Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis model. (1995) (23)
Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. (2007) (23)
Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. (1996) (23)
Management of Thrombotic and Cardiovascular Disorders in the New Millenium (2003) (22)
Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist. (2010) (22)
Diagnostic efficacy of newer synthetic-substrates methods for assessing coagulation variables: a critical overview. (1983) (22)
Pharmacologic profiling of defibrotide in experimental models. (1988) (22)
Patients With a History of Idiopathic Deep Venous Thrombosis Have Long-Term Increased Levels of Inflammatory Markers and Markers of Endothelial Damage (2017) (22)
Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide. (1993) (22)
Review: Contaminants in Heparin: Review of the Literature, Molecular Profiling, and Clinical Implications (2011) (22)
Biomarkers of Inflammation, Thrombogenesis, and Collagen Turnover in Patients With Atrial Fibrillation (2018) (22)
Modulation of smooth muscle responses by serine proteases and related enzymes. (1986) (22)
In Vivo Neutralization of Unfractionated Heparin and Low-Molecular-Weight Heparin by a Novel Salicylamide Derivative (2010) (21)
Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction. (2013) (21)
Factor Xa inhibitors (2004) (21)
European Community and US-FDA Approval of Recombinant Human Antithrombin Produced in Genetically Altered Goats (2009) (21)
The First Report of Successful Carotid Stent Implant Using Argatroban Anticoagulation in a Patient with Heparin-Induced Thrombocytopenia and Thrombosis Syndrome (1998) (21)
Synthetic Heparin Pentasaccharide Depolymerization by Heparinase 1: Molecular and Biological Implications (2001) (21)
Rotational thromboelastometry (ROTEM) profiling of COVID–19 patients (2021) (21)
Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin. (1994) (21)
The metabolic syndrome: definition, diagnosis and management. (2008) (21)
Cyanotic congenital heart disease in children: hemostatic disorders and relevance of molecular markers of hemostasis. (1984) (21)
Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans. (1994) (21)
Antiplatelet action of intravascular contrast media. Implications in diagnostic procedures. (1984) (21)
Behavioral, endocrine, and neurochemical effects of sulfomucopolysaccharide treatment in the aged Fischer 344 male rat. (1991) (20)
INHIBITION OF SERINE PROTEASES BY LOW MOLECULAR WEIGHT PEPTIDES AND THEIR DERIVATIVES (1981) (20)
Right Ventricular Outflow Doppler Predicts Low Cardiac Index in Intermediate Risk Pulmonary Embolism (2019) (20)
Tissue factor pathway inhibitor in thrombosis and beyond. (2004) (20)
Heparin to pentasaccharide and beyond: the end is not in sight. (2004) (20)
Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues. (1993) (20)
Vascular disease: obesity and excess weight as modulators of risk (2011) (20)
Dysregulation of Inflammatory and Hemostatic Markers in Sepsis and Suspected Disseminated Intravascular Coagulation (2015) (20)
Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy (2021) (20)
North American Thrombosis Forum, AF Action Initiative Consensus Document. (2016) (19)
Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: Implications in the HIT pathogenesis (2004) (19)
Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial). (2006) (19)
Practical Issues in the Development of Argatroban: A Perspective (2003) (19)
SYNTHETIC SUBSTRATE ASSAYS OF THE COAGULATION ENZYMES AND THEIR INHIBITORS. COMPARISON WITH CLOTTING AND IMMUNOLOGIC METHODS FOR CLINICAL AND EXPERIMENTAL USAGE (1981) (19)
Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide. (1985) (19)
Biomarker Profile of Sepsis-Associated Coagulopathy Using Biochip Assay for Inflammatory Cytokines (2018) (19)
Section Review—Cardiovascular & Renal: Recent Developments in Antithrombotic Agents (1995) (18)
Point of Care: Diagnostics in Hemostasisthe Wrong Direction? (2003) (18)
Ionic and Non-Ionic Contrast Media Interaction with Anticoagulant Drugs (1982) (18)
Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence. (1984) (18)
In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169). (1985) (18)
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. (1999) (18)
Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin. (1991) (18)
The Available Low Molecular Weight Heparin Preparations Are Not the Same (1997) (18)
Current trends in the development of anticoagulant and antithrombotic drugs. (1994) (18)
Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. (1984) (18)
Performance characteristics of a simple radioimmunoassay for fibrinopeptide A. (1984) (18)
Comparison of Low-Molecular-Weight Heparins Prepared From Bovine Heparins With Enoxaparin (2017) (18)
Idraparinux sodium. Sanofi-Aventis. (2004) (18)
Molecular markers of hemostatic activation. Implications in the diagnosis of thrombosis, vascular, and cardiovascular disorders. (1995) (18)
Monitoring of Argatroban in ARG310 Study: Potential Recommendations for its Use in Interventional Cardiology (2002) (18)
Effect of Bosentan on Plasma Markers of Endothelial Cell Activity in Patients with Secondary Pulmonary Hypertension Related to Connective Tissue Diseases (2009) (18)
Neutralization of recombinant hirudin: some practical considerations. (1991) (18)
Reduction of plasma levels of prothrombin fragments 1 and 2 during thromboprophylaxis with a low‐molecular‐weight heparin (1992) (18)
The use of a HEMOCHRON® JR. HEMONOX™ point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures (2006) (17)
Pharmacology of argatroban (2010) (17)
Comparative Anticoagulant and Platelet Modulatory Effects of Enoxaparin and Sulodexide (2009) (17)
Plasma Thrombin Activatable Fibrinolysis Inhibitor and Tissue Factor Pathway Inhibitor Changes Following Sepsis (2007) (17)
Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems. (1992) (17)
Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum (2019) (17)
Management of Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia and Thrombosis Syndrome (1997) (17)
Newer synthetic peptide substrates in coagulation testing: some practical considerations for automated methods. (1983) (17)
Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. (1992) (17)
Increased Prevalence of Antiheparin Platelet Factor 4 Antibodies in Patients May Be Due to Contaminated Heparin (2009) (17)
Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan. (1991) (17)
Inferior Vena Cava Filters (2013) (17)
Medical management of patients with peripheral arterial disease. (2015) (16)
Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin. (1989) (16)
Feasibility study of heparin mass calibrator as a GPC calibrator for heparins and low molecular weight heparins. (1994) (16)
Laboratory studies on the intravenous and subcutaneous administration of PK 10169 in man. (1986) (16)
Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. (1999) (16)
Anticoagulant and Antiprotease Effects of a Novel Heparinlike Compound From Shrimp (Penaeus brasiliensis) and Its Neutralization by Heparinase I (2001) (16)
Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations (1995) (16)
Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions. (1985) (16)
Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and management. (2008) (16)
Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs. (1993) (16)
Angiopoietin 2 Levels in the Risk Stratification and Mortality Outcome Prediction of Sepsis-Associated Coagulopathy (2017) (16)
Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3. (2002) (16)
Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period. (1995) (16)
Thrombin inhibition with dipeptidyl argininals. (1988) (16)
Warfarin-Induced Skin Necrosis: A Case Report (2006) (16)
Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin (2017) (16)
Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins. (1991) (15)
Synthetic peptide substrates in hemostatic testing. (1983) (15)
Modulation of Endothelium by Heparin and Related Polyelectrolytes (1996) (15)
Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism? (2008) (15)
Singlet oxygen (1O(2)) disrupts platelet aggregates. (2001) (15)
Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (Enoxaparin) versus Dextran 70 in hip arthroplasty. (1991) (15)
Air Travel-Associated Venous Thromboembolism (2003) (15)
Development of generic low molecular weight heparins: a perspective. (2005) (15)
Chemometric analysis of porcine, bovine and ovine heparins (2019) (15)
Soluble Adhesion Molecules in the HIT Syndrome: Pathophysiologic Role and Therapeutic Modulation (1999) (15)
Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate (2022) (15)
Gynecology and Obstetrics (2013) (15)
Low molecular weight heparins: Structural differentiation by spectroscopic and multivariate approaches (2011) (15)
Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels (2019) (15)
Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure (2018) (15)
Current Status of Thrombosis: A Multidisciplinary Medical Issue and Major American Health Problem—Beyond the Year 2000 (1997) (14)
Biomarker profiling of plasma from acute coronary syndrome patients. Application of ProteinChip Array analysis. (2004) (14)
Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs. (1992) (14)
Blood Levels of Nitric Oxide, C-Reactive Protein, and Tumor Necrosis Factor-α Are Upregulated in Patients with Malignancy-Associated Hypercoagulable State: Pathophysiologic Implications (2004) (14)
Simultaneous Monitoring of Argatroban and Its Major Metabolite Using an HPLC Method: Potential Clinical Applications (1999) (14)
Porcine Mucosal Heparin Shortage Crisis! What Are the Options? (2019) (14)
Pyelonephritis during pregnancy: A cause for an acquired deficiency of protein Z (2005) (14)
Effects of a Synthetic Factor Xa Inhibitor (JTV-803) on Various Laboratory Tests (2002) (14)
Pharmacological profiling of recombinant tissue factor pathway inhibitor. (1996) (14)
Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism (2011) (14)
Topical application of low molecular weight heparin in a rabbit traumatic anastomosis model. (1997) (14)
Update of the recommendations on biosimilar low‐molecular‐weight heparins from the Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis (2013) (14)
Molecular profile and mapping of dermatan sulfates from different origins. (1991) (14)
Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values (2019) (14)
Pharmacokinetics of native and low molecular weight dermatans: preliminary studies in rats and primates. (1991) (14)
Low molecular weight heparins: a developmental perspective. (1997) (14)
Laboratory evaluation of the antiphospholipid syndrome. (2008) (14)
Increased Level of Thrombotic Biomarkers in Patients with Atrial Fibrillation Despite Traditional and New Anticoagulant Therapy (2016) (13)
A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty. (2001) (13)
Preclinical studies on a low molecular weight heparin. (1996) (13)
Automation and quality control in the coagulation laboratory. (1994) (13)
Biochemical evidence for a relative lack of inhibition of thrombin formation by nonionic contrast media. (1991) (13)
Compositional Differences in Commercially Available Prothrombin Complex Concentrates (2012) (13)
Automation of plasma antithrombin III assays. (1981) (13)
In vitro studies on the biochemistry and pharmacology of low molecular weight heparins. (1999) (13)
Increased Expression of Secreted Frizzled-Related Protein-1 and Microtubule-Associated Protein Light Chain 3 in Keratoconus (2013) (13)
Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. (1996) (13)
Inflammatory Biomarker Profiling in Total Joint Arthroplasty and Its Relevance to Circulating Levels of Lubricin, a Novel Proteoglycan (2018) (13)
Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers. (1992) (13)
The future of anticoagulation. (2008) (13)
Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? (2008) (13)
Molecular markers of hemostatic activation in atherosclerosis: a new concept in diagnostic profiling of endogenous pathophysiologic transition. (1986) (13)
Upregulation of Surrogate Markers of Inflammation and Thrombogenesis in Patients With ESRD: Pathophysiologic and Therapeutic Implications (2011) (13)
Modifications of plasma levels of tissue factor pathway inhibitor and endothelin-1 induced by a reverse Trendelenburg position: influence of elastic compression--preliminary results. (1995) (13)
Biomarkers of Platelet Activation and Their Prognostic Value in Patients With Sepsis-Associated Disseminated Intravascular Coagulopathy (2021) (13)
Sustained Release of Tissue Factor Following Thrombosis of Lower Limb Trauma (2014) (12)
Pharmacokinetics of heparins differing in mean molecular weight using a Xa amidolytic and Heptest clotting method. (1988) (12)
Inhibition of the contractile action of bradykinin on isolated smooth muscle preparations by derivatives of low molecular weight peptides. (1979) (12)
Ischemic Stroke in the Setting of Chronic Immune Thrombocytopenia in an Elderly Patient—A Therapeutic Dilemma (2012) (12)
Drug-induced alterations of hemostasis and fibrinolysis. (1992) (12)
Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty (2017) (12)
Interrelationship of Osteopontin, MMP-9 and ADAMTS4 in Patients With Osteoarthritis Undergoing Total Joint Arthroplasty (2020) (12)
Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression. (2000) (12)
Effects of adjunctive inflammatory modulation on IL-1β in treatment resistant bipolar depression (2020) (12)
Tissue factor pathway inhibitor for cardiovascular disorders (2000) (12)
Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa (2020) (12)
State-of-the-Art-Review : Thrombogenesis in Myocardial Infarction and Related Syndromes: The Role of Molecular Markers in Diagnosis and Management (1999) (12)
The low molecular weight heparins dalteparin sodium inhibits angiogenesis and induces apoptosis in an experimental tumour model. (2003) (12)
In vitro Simulation of Therapeutic Plasmatic Fibrinolysis (2003) (12)
Successful Use of Recombinant Hirudin and Its Monitoring by Ecarin Clotting Time in Patients with Heparin‐Induced Thrombocytopenia Undergoing Off‐Pump Coronary Artery Revascularization (2005) (12)
A new approach in monitoring recombinant hirudin during cardiopulmonary bypass. (1993) (12)
Heparin and a cyclic octaphenol-octasulfonic acid (GL-522-Y-1) bind with high affinity to a 47-kda protein from vascular endothelial cell surface and stimulate the synthesis and structural changes of heparan sulfate proteoglycan. (2001) (12)
Modulation of endothelial and platelet function by a polydeoxyribonucleotide derived drug "defibrotide". A dual mechanism in the control of vascular pathology. (1993) (11)
New and Generic Anticoagulants and Biosimilars: Safety Considerations (2011) (11)
Antithrombin Agents as Anticoagulants and Antithrombotics: Implications in Drug Development (1998) (11)
IBC’s 11th Annual International Symposium: Advances in Anticoagulant, Antithrombotic and Thrombolytic Drugs (2001) (11)
Platelet activation by human pancreatic fluid. (1984) (11)
The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper (2021) (11)
Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications. (2004) (11)
Is the Reason of Increased D-Dimer Levels in COVID-19 Because of ACE-2-Induced Apoptosis in Endothelium? (2020) (11)
Singlet oxygen (1O2) Inactivates Plasmatic Free and Complexed α2-Macroglobulin (2000) (11)
Vascular endothelial growth factor in bipolar depression: A potential biomarker for diagnosis and treatment outcome prediction (2020) (11)
Fibrinolytic Dysregulation in Total Joint Arthroplasty Patients (2016) (11)
Laser nephelometric quantitation of antithrombin-III (AT-III) development of a new assay. (1981) (11)
Inflammatory and Procoagulant Cytokine Levels During Pregnancy as Predictors of Adverse Obstetrical Complications (2014) (11)
Thrombomodulin alfa attenuates the procoagulant effect and cytotoxicity of extracellular histones through the promotion of protein C activation. (2017) (11)
Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins (2019) (11)
Overview: from heparin to low molecular weight heparin: beyond anticoagulation. (2001) (11)
Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3. (2014) (11)
Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs. (1993) (11)
A consensus conference on complex biologics and low molecular weight heparins. (2010) (11)
Perioperative Factors and Their Effect on the Fibrinolytic System in Arthroplasty Patients (2016) (11)
Leading Article: Cardiovascular & Renal: Recombinant hirudin: A perspective (1996) (11)
Determination of specific activity of recombinant hirudin using a thrombin titration method. (1995) (11)
In vitro protamine neutralization profiles of heparins differing in source and molecular weight. (1989) (11)
A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. (2011) (10)
Glycosaminoglycan backbone is not required for the modulation of hemostasis: effect of different heparin derivatives and non-glycosaminoglycan analogs. (2012) (10)
Rationale for the management of coronary syndromes with low-molecular-weight heparins. (1998) (10)
Why differentiate low molecular weight heparins for venous thromboembolism? (2007) (10)
Treatment for Patients With Cancer (2013) (10)
Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin. (1997) (10)
A serotonin and βHCG‐producing islet cell carcinoma associated with focal nodular hyperplasia of the liver (1983) (10)
Impact of automation on the quantitation of low molecular weight markers of hemostatic defects. (1983) (10)
Differentiation of Low-Molecular-Weight Heparins: Practical Implications (2004) (10)
Matrix Metalloproteinases and Their Inhibitors and Proteoglycan 4 in Patients Undergoing Total Joint Arthroplasty (2019) (10)
Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model. (1991) (10)
Neurotrophic Effects of the Glycosaminoglycan C3 on Dendritic Arborization and Spines in the Adult Rat Hippocampus: A Quantitative Golgi Study (2006) (10)
Development of a Synthetic Heparin Pentasaccharide: Fondaparinux. (2002) (10)
An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations (2022) (10)
The antithrombotic factor singlet oxygen/light (1O2/h nu). (2000) (10)
Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review (2020) (10)
Tissue Factor Pathway Inhibitor and Thrombin Activatable Fibrinolytic Inhibitor Plasma Levels following Burnand Septic Injuries in Rats (2004) (10)
Comparative studies on the inhibitory spectrum of recombinant hirudin, DuP 714 and heparin on thrombin and factor Xa generation in biochemically defined systems. (1994) (10)
Mass balance analysis of contaminated heparin product. (2011) (10)
Pharmacologic profile of certoparin. (1999) (10)
Lupus anticoagulant assays. (1994) (10)
Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients. (2003) (10)
Characterization of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential (2017) (10)
Structural and Functional Characterization of Low-molecular-weight Heparins: Impact on the Development of Guidelines for Generic Products (2009) (10)
Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfate. (1992) (10)
US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins (2012) (10)
In vitro studies on the effect of activated protein C on platelet activation and thrombin generation. (1997) (9)
Contrast Media Induced Serotonin Release in Human Blood (1982) (9)
Improving reliability of chemometric models for authentication of species origin of heparin by switching from 1D to 2D NMR experiments (2018) (9)
Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effects. (1990) (9)
International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treatment and Disseminated Intravascular Coagulation (2018) (9)
Plasma MCP-1 levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment. (2020) (9)
Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited. (2002) (9)
STUDIES ON A HIGHLY POTENT ANTICOAGULANT ANIONIC HIGH MOLECULAR WEIGHT FRACTION ISOLATED FROM PORCINE HEPARIN (1981) (9)
Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin. (1991) (9)
Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamine. (1992) (9)
Low Molecular Weight Heparins (1992) (9)
Response to Maccio et al, “Multifactorial pathogenesis of COVID‐19‐related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?” (2020) (9)
Comparative Tissue Factor Pathway Inhibitor Release Potential of Heparins (2005) (9)
Periprocedural management of antithrombotic therapy and use of bridging anticoagulation. (2013) (9)
Pharmacokinetics and Pharmacodynamics of Argatroban as Studied by HPLC and Functional Methods: Implications in the Monitoring and Dosage-Optimizations in Cardiovascular Patients (1998) (9)
A Review of its Pharmacology and Clinical Use in the Prevention and Treatment of Thromboembolic Disorders (1997) (9)
Levels of Matrix Metalloproteinases in Arthroplasty Patients and Their Correlation With Inflammatory and Thrombotic Activation Processes (2016) (9)
Effects of a heparin-binding protein on blood coagulation and platelet function. (2001) (9)
Effect of 1,6-Anhydro Bicyclic Ring Structure on the Pharmacokinetic and Pharmacodynamic Behavior of Low Molecular Weight Heparin. (2004) (9)
Influence of heparins on inositol 1,4,5-trisphosphate-induced calcium mobilization in permeabilized human platelets. (1991) (9)
Contaminant in the Recalled Unfractionated Heparin Preparations: Where is the Problem? (2008) (9)
Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature review. (2004) (9)
Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins. (1995) (9)
Difficulties of Managing Submassive and Massive Pulmonary Embolism in the Era of COVID-19 (2020) (9)
[Low molecular weight oligosaccharides active in plasma against factor Xa. II. New structural elements and antithrombotic activity (author's transl)]. (1981) (9)
Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies. (2002) (9)
1995 American College of Chest Physicians (ACCP) consensus guidelines on antithrombotic therapy. (1996) (9)
Emerging anticoagulant and thrombolytic drugs (2001) (9)
Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist. (2001) (9)
Factor Xa Inhibitors in the Control of Thrombogenesis (1999) (9)
New class of heparin derivatives with a potent antithrombotic effect and a very limited hemorrhagic activity. (1996) (9)
An Open Label, Non-randomized, Prospective Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars in Healthy Volunteers (2011) (9)
Antithrombotic therapy in 2014: Making headway in anticoagulant and antiplatelet therapy (2015) (9)
The Immunogenic Potential of Generic Version of Low-Molecular-Weight Heparins May Not be the Same as the Branded Products (2008) (9)
Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin). (1993) (9)
The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models. (1993) (9)
Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy. (1995) (9)
Molecular weight profiling of low molecular weight heparins utilizing a heparinase degraded oligosaccharide mixture as a calibrator. (1993) (8)
d-Dimer Levels are Significantly Increased in Blood Taken From Varicose Veins Compared With Antecubital Blood From the Same Patient (2015) (8)
Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods. (1999) (8)
Molecular markers of hemostatic activation: future perspectives. (1984) (8)
Generic Low Molecular Weight Heparins: A Significant Dilemma (2005) (8)
Combined Thrombin and Platelet Inhibition Treatment for HIT Patients (1999) (8)
A supersulfated low‐molecular‐weight heparin (IK‐SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans (1998) (8)
Effects of protease inhibitors on coagulation abnormalities in acute canine pancreatitis. (1984) (8)
Studies on the thrombogenic effects of recombinant tissue factor. In vivo versus ex vivo findings. (1995) (8)
Immune Responses Associated With Perioperative Exposure and Reexposure to Topical Bovine Thrombin Do Not Impair Hemostasis (2011) (8)
Basic and Clinical Differences of Heparin and Low Molecular Weight Heparin Treatment (2005) (8)
A Comparison of the Pharmacodynamic Behavior of Branded and Biosimilar Enoxaparin in Primates (2012) (8)
Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome. (2019) (8)
BETAINE INDUCED RELEASE OF TISSUE FACTOR PATHWAY INHIBITOR AND NITRIC OXIDE: IMPLICATIONS IN THE MANAGEMENT OF CARDIOVASCULAR DISEASE (2006) (8)
Studies on the Effect of Calcium in Interactions Between Heparin and Heparin Cofactor II Using Surface Plasmon Resonance (2004) (8)
Comparison of outcomes in catheter-directed versus ultrasound-assisted thrombolysis for management of submassive pulmonary embolism. (2021) (8)
Defibrotide Blunts the Prothrombotic Effect of Thalidomide on Endothelial Cells (2012) (8)
Tissue Factor-Mediated Activation of the Prothrombin Complex Concentrate (PCC) is Differently Inhibited by Dabigatran, Rivaroxaban, and Apixaban (2013) (7)
Anticoagulant activity of porcine heparin: Structural-property relationship and semi-quantitative estimation by nuclear magnetic resonance (NMR) spectrometry. (2019) (7)
Modified crush‐avulsion anastomosis model on the rat femoral vein (1995) (7)
Molecular markers of hemostatic activation and inflammation following major injury: effect of therapy with IFN-gamma. (1998) (7)
Protein C levels in activated and non-activated prothrombin complex concentrates (1984) (7)
Nitric oxide branch of arginine metabolism in depression: effect of venlafaxine. (2009) (7)
Use of recombinant hirudin to increase the patency rate of microanastomosis in a rabbit model. (1991) (7)
Incidence of Antiheparin−Platelet Factor 4 Antibodies and Heparin-Induced Thrombocytopenia in Turkish Patients Undergoing Cardiac Surgery (2007) (7)
Prevalence of Metabolic Syndrome in Patients with End Stage Renal Disease and Relevance of Biomarkers (2015) (7)
Diagnosis and Anticoagulant Treatment * (2013) (7)
Automated clot-based methods in coagulation testing: current and future considerations. (1983) (7)
Recombinant hirudin as an antithrombotic drug: current status and future perspectives (1990) (7)
Metabolic differences of current thienopyridine antiplatelet agents (2013) (7)
Lack of inhibition of thrombin generation by nonionic contrast media. (1991) (7)
Antagonism of the bradykinin induced contractile response of isolated smooth muscle preparations by low molecular weight synthetic chromogenic peptide substrates for serine proteases. (1978) (7)
Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin (2008) (7)
Reference Ranges of the Dilute Tissue Thromboplastin Inhibition and Dilute Russell's Viper Venom Tests Revisited (2002) (7)
Automated instrumentation and the laboratory diagnosis of bleeding and thrombotic disorders. (1983) (7)
Periprocedural Management of Antithrombotic Therapy and Use of Bridging Anticoagulation (2008) (7)
Low molecular weight heparins. An objective overview. (1992) (7)
Acute Myocardial Infarction in a Patient with Essential Thrombocythemia Treated with Glycoprotein Ilb/Illa Inhibitor (2004) (7)
Textbook of Interventional Cardiovascular Pharmacology (2007) (7)
Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling (2021) (7)
Osteopontin Levels in Patients With Chronic Kidney Disease Stage 5 on Hemodialysis Directly Correlate With Intact Parathyroid Hormone and Alkaline Phosphatase (2019) (7)
Thrombin Generation Inhibition by Newer Anti Xa and Anti IIa Drugs in Prothrombin Complex Concentrates: Relevance to Endogenous Modulation of Thrombogenesis (2011) (7)
Resourcing of Heparin and Low Molecular Weight Heparins from Bovine, Ovine, and Porcine Origin. Studies to Demonstrate the Biosimilarities (2015) (7)
AVE5026: A new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis (2008) (7)
Comparative Studies on Branded Enoxaparin and a US Generic Version of Enoxaparin (2013) (7)
Fibrinolytic Deficit and Platelet Activation in Atrial Fibrillation and Their Postablation Modulation (2018) (6)
Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in End-stage Renal Disease (2016) (6)
Thrombolytic drugs in acute myocardial infarction. (2000) (6)
Clinical applications of bioinformatics, genomics, and pharmacogenomics. (2006) (6)
Early recanalization of veins in patients with DVT treated with rivaroxaban: do we need to move from bedside to bench again? (2018) (6)
Recombinant hirudin--initial observations in reconstructive microsurgery. (1991) (6)
Influence of hypersulfated lactobionic acid amides on tissue plasminogen activator release. (1991) (6)
In vitro Heparan Sulfate Modulates the Immune Responses of Normal and Tumor-Bearing Mice (2007) (6)
Antithrombotic drugs in pelvic surgery. (1989) (6)
Upregulation of Microparticles in DIC and its Impact on Inflammatory Processes (2011) (6)
Synthetic and recombinant antithrombin drugs. (1998) (6)
Report on a discussion forum: "Medical and surgical application of recombinant hirudin". (1991) (6)
Elevated endocan levels and its association with clinical severity in Stevens-Johnson Syndrome and toxic epidermal necrolysis. (2015) (6)
The Effects of Intermittent Pneumatic Compression on Systemic and Local Fibrinolysis (1999) (6)
An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients. (2009) (6)
Pulmonary embolism response team implementation improves awareness and education among the house staff and faculty (2019) (6)
Medical patients. (2013) (6)
Development of fibrinopeptide A generation tests in the evaluation and the monitoring of the action of heparin and its low molecular weight fractions. (1984) (6)
The Role of Thrombolytic Drugs in the Management of Acute Myocardial Infarction and Stroke. (2002) (6)
Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplasty. (1991) (6)
Plasma thrombomodulin level as a predictor of hemorrhagic (and thrombotic) events in patients on long-term anticoagulant treatment. (1997) (6)
Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels (2011) (6)
Advances in Heparins and Related Research. An Epilogue (2018) (6)
Ecarin Clotting Time is Sensitive to Heparinoids: Comparison of Two Different Techniques (2001) (6)
Pathophysiology of Heparin-Induced Thrombocytopenia (2000) (6)
Biochemical and pharmacologic profile of defined molecular weight fractions of heparin. (1993) (6)
Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effects. (1989) (6)
In vivo Heparan Sulfate Treatment Alters the Immune Response of Normal and LLC-Bearing Mice (2006) (6)
A survey of venous thrombosis models. (2004) (6)
Variations in the Circulating Heparin Levels During Maintenance Hemodialysis in Patients With End-Stage Renal Disease (2013) (6)
The Risk of Venous Thromboembolism is Not Equal for all Patients Who Undergo Total Joint Replacement (2019) (6)
A comparative study on the mechanism of the anticoagulant action of mollusc and mammalian heparins. (1995) (6)
Inflammatory Biomarker Profiling in Elderly Patients With Acute Hip Fracture Treated With Heparins (2010) (6)
A Perspective on Low Molecular Weight Heparins in the Management of Thrombosis (1993) (6)
Anticoagulant and antithrombotic actions of a semisynthetic beta-1,3-glucan sulfate. (1995) (6)
Neurological Complications of Pulmonary Embolism: a Literature Review (2021) (6)
Studies On The Mechanism Of Heparin Induced Thrombocytopenia (1981) (5)
A Survey of Animal Models to Develop Novel Antithrombotic Agents (2002) (5)
Biomarker profiling of plasma samples utilizing RANDOX biochip array technology. (2017) (5)
Validation of the European Pharmacopeial method for molecular weight profiling of low molecular weight heparins: comparative studies utilizing an improved calibrator, ITH-3. (1993) (5)
Epilogue: The Management of Thrombotic and Cardiovascular Disorders in the 21st Century (2002) (5)
Systematic analysis of enoxaparins from different sources with online one- and two-dimensional chromatography. (2019) (5)
Reduced Immunogenic Potential of Membrane Filtered Bovine Thrombin Preparations for Hemostatic Application (2009) (5)
Unfractionated and Low-Molecular-Weight Heparins, Basic Mechanism of Action and Pharmacology (2003) (5)
State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction (2000) (5)
Upregulation of Inflammatory Mediators in End-Stage Renal Disease as Measured Using Biochip Array Technology (2011) (5)
Validation of a Gravitational Model to Study Local Endogenous Biomarkers in Chronic Venous Insufficiency. (2018) (5)
Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins. (2012) (5)
Plasma Tissue Factor Pathway Inhibitor Levels as a Marker for Postoperative Bleeding After Enoxaparin Use in Deep Vein Thrombosis Prophylaxis in Orthopedics and General Surgery (2000) (5)
Global Anticoagulant Effects of a Novel Sulfated Pentomanan Oligosaccharide Mixture (2001) (5)
Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product (2014) (5)
Argatroban Treatment for Patients with Intoleranceto Heparin and Hirudin (2005) (5)
Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor. (2004) (5)
Structural characterization of a clinically described heparin-like substance in plasma causing bleeding. (2020) (5)
Biomarker Profiling in Stage 5 Chronic Kidney Disease Identifies the Relationship between Angiopoietin-2 and Atrial Fibrillation (2018) (5)
Vitamin D and Postoperative Vasopressor Use in Cardiopulmonary Bypass (2018) (5)
Thrombin Generation Mediators and Markers in Sepsis Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin (2012) (5)
Fibrinolytic Compromise by Synthetic and Recombinant Thrombin Inhibitors: Implications in the Treatment of Thrombotic Disorders (1995) (5)
Are the Current Guidelines for the Acceptance of Generic Low Molecular Weight Heparins Adequate? (2003) (5)
Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro (2018) (5)
Laboratory Diagnosis of Heparin-Induced Thrombocytopenia in Asian Indians as Investigated With Functional and Immunologic Methods (2004) (5)
The use of defibrotide in BMT-associated veno-occlusive disease (1995) (5)
Role of splenic red pulp in endotoxin-induced disseminated intravascular coagulation. (1981) (5)
Sunday, 26 August 2012 (2012) (5)
Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model. (1996) (5)
Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo--studies of venous and arterial thrombosis. (1999) (5)
Thrombogenesis in myocardial infarction and related syndromes: the role of molecular markers in diagnosis and management. (1999) (5)
Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial rings. (1996) (5)
Pharmacodynamics of a sulfated lactobionic acid amide-derived antithrombotic agent (Aprosulate) in primates. (1991) (5)
Development of an Algorithm to Predict Mortality in Patients With Sepsis and Coagulopathy (2018) (5)
Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs (2014) (5)
Current status on new anticoagulant and antithrombotic drugs and devices (1997) (5)
The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (2021) (5)
Venous thromboprophylaxis in the 1990s: a perspective. (1991) (5)
COVID-19 PANDEMIC UPDATES AND PERSPECTIVES. NEED FOR AN INTEGRATED AND EQUITABLE APPROACH. (2021) (5)
Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population? (2017) (4)
Procalcitonin as a Marker of Comorbid Atrial Fibrillation in Chronic Kidney Disease and History of Sepsis (2020) (4)
Modulatory Effects of Escherichia coli Capsular–Derived Sulfaminoheparosans and Heparins on Tissue Factor–Mediated Activation of Platelets: Flow Cytometric Analysis (2006) (4)
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. (2011) (4)
Current trends in hemostatic testing. (1983) (4)
Differential Effects of DX-9065a, Argatroban, and Synthetic Pentasaccharide on Tissue Thromboplastin Inhibition Test and Dilute Russell's Viper Venom Test (2003) (4)
Pharmacological profile of reviparin-sodium. (1993) (4)
Differential augmentation of the anticoagulant responses by newly developed oral anti‐Xa and Anti‐IIa drugs in patients with liver disease (2009) (4)
Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide (2018) (4)
Comparison of Immunogenic Potentials of Bovine Thrombin Preparations (2009) (4)
Levels of Matrix-Degrading Enzymes and Lubricin in Patients With Degenerative Joint Disease Requiring Arthroplasty (2018) (4)
Internal and external validation of THROLY (thrombosis lymphoma) score (2018) (4)
Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients (2021) (4)
Inhibitory effects of TFPI variants on thrombin and factor Xa generation in fibrinogen-deficient human plasma. (1994) (4)
Contaminants in heparins continue to be unfolded. (2008) (4)
Prevalence of metabolic syndrome in patients undergoing total joint arthroplasty and relevance of biomarkers. (2016) (4)
Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy. (2020) (4)
Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin. (1995) (4)
Influence of Different Anticoagulant Agents on Fibrinopeptide A Generation (2003) (4)
Analysis of 3-O-Sulfated Heparan Sulfate Using Isotopically Labeled Oligosaccharide Calibrants. (2022) (4)
Resourcing of Heparin and Low-Molecular-Weight Heparins from Bovine, Ovine, and Porcine Origin: Studies to Demonstrate the Biosimilarities (2016) (4)
Thrombin Induced Contraction Of Isolated Smooth Muscles (1981) (4)
Ethylenediaminetetraacetic acid (EDTA) in heparin. (1998) (4)
Influence of synthetic sulfated bis-lactobionic acid amides on tissue-type plasminogen activator release. (1991) (4)
Protamine sulfate neutralization of the anticoagulant activity of Aprosulate, a synthetic sulfated lactobionic acid amide. (1994) (4)
Hostile personality characteristics and prostaglandins in essential hypertension. (1989) (4)
Current perspectives on low molecular weight heparins. (1993) (4)
Cross-Reactivity of Various Thrombin Products With Anti-Rabbit Antibodies to Bovine, Human, and Recombinant Thrombin (2012) (4)
Current Developments in Anticoagulant and Antithrombotic Agents (1999) (4)
Functional characterization of antibodies against heparin–platelet factor 4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: relevance to inflammatory markers (2005) (4)
Global Anticoagulant Effects of a Synthetic Anti-Factor Xa Inhibitor (DX-9065a): Implications for Interventional Use (2003) (4)
Crude Heparin Preparations Unveil the Presence of Structurally Diverse Oversulfated Contaminants (2019) (4)
Pre- vs postoperative pharmacologic inhibition of platelets: effect on intimal hyperplasia in canine autogenous vein grafts. (1992) (4)
Molecular and functional heterogeneity in dermatan sulfate preparations. (1991) (4)
Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes (2021) (4)
Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions. (1996) (4)
Key questions to be answered. (2013) (4)
Comparative study of protease inhibitors on coagulation abnormalities in canine pancreatitis. (1984) (4)
[Concerns on generic enoxaparin use in acute coronary syndrome]. (2010) (4)
Impact of biotechnology in the diagnostic and therapeutic management of cardiovascular disorders. (1995) (4)
The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients (2022) (4)
Laboratory analysis of blood samples from patients treated with tinzaparin. (2004) (4)
Structural and Pharmacological Profile of Generic Enoxaparins Used in Brazil (2012) (4)
Interrelationship of MMP-9, Proteoglycan-4, and Inflammation in Osteoarthritis Patients Undergoing Total Hip Arthroplasty (2021) (4)
Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components (2020) (4)
Piracetam: A New Platelet Suppressing Drug (1981) (4)
Relationship Between 25-Hydroxyvitamin D, Renin, and Collagen Remodeling Biomarkers in Atrial Fibrillation (2020) (4)
The Anti-Inflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Inhibitors: Experimental and Clinical Observations (2008) (3)
Inflammation and Hemostatic Activation may Contribute to Postsurgical Thrombosis in Patients With Bladder Cancer (2016) (3)
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM.International Consensus Statement. Guidelines compiled in accordance with the scientific evidence (2006) (3)
Arterial-renal Syndrome in Patients with ESRD, a New Disease Paradigm (2022) (3)
Isoamyl Nitrite Depolymerized Heparin as a Universal Calibrator for Heparins and Low Molecular Weight Heparins (2000) (3)
Procoagulant and Anticoagulant Effects of Intravascular Contrast Media as Assessed by Thromboelastography (1995) (3)
Assay Dependent Variations in the Anticoagulant and Protamine Sulfate Neutralization Profiles of Generic Copies of Enoxaparin. (2006) (3)
TFPI Release by GAGs and Its Role in Their Mechanism of Action (1996) (3)
Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by Novel Salicylamide Derivatives (2007) (3)
Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs (2013) (3)
Biomarkers of Hemostatic Dysregulation and Inflammation in Lymphoma: Potential Relevance to Thrombogenesis (2019) (3)
Prevention of postthrombotic syndrome. (2013) (3)
Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery. (2000) (3)
Evaluation of thrombin activity by immunoquantitation of fibrinopeptide A generation. (1986) (3)
Substituted azopurines. 1. Synthesis of 8,8'-dioxo-6,6'-azopurine. (1974) (3)
Efficacy of S-2441, a synthetic oligopeptide, in a rat model for gram-negative bacteremia. (1985) (3)
2. Tumor Necrosis Factor alpha as a biomarker in major depressive disorder (2012) (3)
Elevated extracellular nucleosomes and their relevance to inflammation in stage 5 chronic kidney disease. (2018) (3)
Low Molecular Weight Heparins: Pharmacology, in vitro and ex vivo Effects and Clinical Results 4th Congress on Thrombosis and Haemostasis Research, Dsseldorf, October 1986 (1988) (3)
Point of Care Monitoring of Enoxaparin in the Presence of GpIIb/IIIa Combined Therapy During Percutaneous Coronary Interventions (PCI) (2004) (3)
A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation (2012) (3)
Relative Neutralization of the Biological Actions of Sulfaminoheparosans (K5 Derivatives) and Heparins by Protamine Sulfate (2007) (3)
Thoracic splenosis. (1985) (3)
Comparison of Ufh and Enoxaparin Originated from Bovine, Ovine and Porcine Mucosa with Functional Coagulation Assays (2016) (3)
Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019? (2019) (3)
Role of PAI-1 and TAFI in the mediation of fibrinolytic deficit in cancer patients (2004) (3)
Unlike Heparins Newer Oral Anticoagulants Do Not Interact with HIT Antibodies and Maybe Useful in the Longterm Anticoagulant Management of Heparin Compromised Patients (2011) (3)
Potential Thrombogenic Complications With the Use of Recombinant Activated Factor VII in Combat Trauma (2007) (3)
Biochemical and pharmacological considerations in the development of heparin and its depolymerized derivatives (1986) (3)
Immunoenzymatic and Biochip Array Profiling of the Biomarkers of Inflammation and Hemostatic Activation Processes in ESRD (2015) (3)
Sticky Platelet Syndrome: The Clinical Spectrum of Thrombosis. (2005) (3)
Cost-Effectiveness of Prevention and Treatment of VTE (2013) (3)
Heparin-PF4 Antibodies in Heparin Induced Thrombocytopenia: Its Relationship with FcgRIIa Polymorphism (2005) (3)
Effect of heparin and heparin fractions on experimental abscess formation. (1986) (3)
The Effects of Rosiglitazone Treatment on the Fibrinolytic System in Patients with Type 2 Diabetes Mellitus (2006) (3)
Differential thrombin generation inhibition by branded and generic low molecular weight heparins (LMWHs) as studied using a fluorescence substrate based kinetic method (2009) (3)
Laboratory application of radioimmunoassay in the quantitation of molecular markers of hemostatic activation. (1984) (3)
Argatroban, Not Lepirudin or Bivalirudin, Treatment Results in the Generation of Nitric Oxide during Parenteral Administration. (2004) (3)
Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates. (2003) (3)
The Protective Effect of Poloxamer-188 on Platelet Functions (2017) (3)
PATHOGENESIS OF ATRIAL FIBRILLATION‐POTENTIAL ROLE OF INFLAMMATORY RESPONSE. (2006) (3)
Postoperative Changes in the Systemic Inflammatory Milieu in Older Surgical Patients (2017) (3)
Rivaroxaban for post-discharge thromboprophylaxis: the MARINER trial. (2018) (3)
Pharmacokinetics of argatroban in primates: evidence on endogenous uptake. (2000) (3)
Time Course of Inflammatory and Procoagulant Markers in the Early Period After Total Hip Replacement (2021) (3)
Angiopoietin-2 correlates with pulmonary embolism severity, right ventricular dysfunction, and intensive care unit admission (2021) (3)
Modulation of Interleukins in Sepsis-Associated Clotting Disorders (2017) (3)
Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractions. (1985) (3)
Comparison of the Anticoagulant Activities of Thrombin Inhibitors as Assessed by Thromboelastographic Analysis (1995) (3)
Measurement of the Antithrombin III Binding Sites in Low Molecular Weight Heparins by 13C NMR and Capillary Electrophoresis (1995) (3)
Safety and Efficacy of Thrombin-JMI: A Multidisciplinary Expert Group Consensus (2011) (3)
Antithrombotic agents in the treatment of severe sepsis (2002) (3)
Effect of Dabigatran and Rivaroxaban on thrombomodulin mediated activation of protein C and thrombin activated fibrinolysis inhibitor (TAFI) (2012) (3)
A Comparison of Ovine and Porcine Heparins and Enoxaparins: A Case for an Alternative Source of Heparin Products (2016) (3)
Cost-effectiveness of prevention and treatment of VTE. (2013) (3)
Endogenous pro-thrombotic biomarkers from the arm and leg may not have the same value (2016) (3)
Increased levels of inflammatory mediators in lung cancer and their modulation by oral anticoagulant treatment. (2006) (3)
Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate. (2008) (3)
1. Interleukin-6 as a biomarker in major depressive disorder (2012) (3)
Assessment of Levels of Vascular Endothelial Growth Factor in Patients With ESRD and Its Possible Role in Cardiovascular Morbidity and Mortality (2012) (2)
Biomarkers of Thrombo-Inflammatory Responses in Pulmonary Embolism Patients With Pre-Existing Versus New-Onset Atrial Fibrillation (2021) (2)
Comparative Studies on the Topical Administration of Mucopolysaccharide and Heparin Ointments in Nonhuman Primates (2010) (2)
Molecular weight and biochemical profile of a chemically modified heparin derivative, Suleparoide. (1993) (2)
Comparison of an intravenous bolus of enoxaparin versus unfractionated heparin in elective coronary angioplasty (1999) (2)
Singlet Oxygen Inhibits Agonist-Induced P-Selectin Expression and Formation of Platelet Aggregates (2001) (2)
Evaluation of hematologic alterations associated with daily administration of low molecular weight heparin (Mono-Embolex) for a 12-week period. (1993) (2)
Synthetic, organic compound vepoloxamer (P‐188) potentiates tissue plasminogen activator (2018) (2)
Increased blood levels of inflammatory cytokines CRP, TNF-α, CD40L, MCP-1 and Nitric Oxide in malignancy-associated thrombosis and their modulation by a low molecular weight heparin, Enoxaparin (2004) (2)
Protamine sulfate neutralization of lactobionic acid amides. (1991) (2)
Oral Factor Xa and Direct Thrombin Inhibitors: A Clinical Perspective (2012) (2)
Cross-Reactivity of Rabbit Anti-Bovine Thrombin IgGs With Human α-Thrombin and a Recombinant Version of Human Thrombin (Recothrom) (2010) (2)
Newer Oral Anticoagulants: A Promising Future (2011) (2)
Procoagulant Actions of Circulating Microparticles in Sickle Cell Anemia and Sepsis Associated Coagulopathy and Their Modulation By a Triblock Polymer MST 188 (2014) (2)
Neutralization Of Hemorrhage Induced By Direct Factor Xa and Thrombin Inhibitors In a Rat Model (2013) (2)
Molecular and Pharmacologic Profile of Tinzaparin and A Comparable Low-Molecular-Weight Bacterial Sulfaminoheparosan (2004) (2)
Modulation of Platelet Function by Recombinant Thrombomodulin Hematologic Implications (2007) (2)
Immune Response Following Exposures to Topical Bovine Thrombin Does Not Impair Hemostasis (2010) (2)
Effect Of Dabigatran and Rivaroxiban On Thrombomodulin Mediated Activation Of Protein C and Thrombin Activated Fibrinolysis Inhibitor (TAFI). Potential Clinical Implications (2013) (2)
General, Vascular, Bariatric, and Plastic Surgical Patients (2013) (2)
Inflammatory and Thrombotic Mediators in Small Cell Lung Carcinoma: Potential Role in Thromboembolic Complications (2011) (2)
Pharmacologic profile of sulfamino-galactosaminoglycans. (1991) (2)
Singlet oxygen ((1)O2) inactivates plasmatic free and complexed alpha2-macroglobulin. (2000) (2)
Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates. (2000) (2)
Potency Adjusted Generic Versions of Argatroban can be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays. (2007) (2)
Studies Related To Tobacco Glycoprotein: A Claimed Activator Of Coagulation, Fibrinolysis, Complement, Kinin, And A Claimed Allergen (1981) (2)
Hemodialysis Mediated Upregulation of Myeloperoxidase in End Stage Renal Disease: Pathophysiologic Implications (2007) (2)
Urgent Interventional Therapies (2014) (2)
Update on the clinical applications of argatroban. (2006) (2)
Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin (2018) (2)
Dr. Eberhard F. Mammen Remembered: A Great Clinician-Scientist, Mentor, and Friend (2008) (2)
Antidotes for the new oral anticoagulant drugs! (2019) (2)
In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723. (1993) (2)
Post-infarct fibrinolytic activity: Inhibition by Trasylol☆ (1976) (2)
Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group (2020) (2)
External Validation and Revision of Thrombosis Lymphoma /Throly/ Score (2018) (2)
Pharmacodynamic differences between biosimilar and branded enoxaparins with reference to their immunogenic profile (2010) (2)
Author / Subject Indexes (1988) (2)
Pharmacologic profile of a low-molecular-weight heparin depolymerized by gamma-irradiation. (1995) (2)
Differential Immunogenic Responses of Branded and Generic Versions of Low Molecular Weight Heparins (2010) (2)
Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint. (2018) (2)
drug interactions of oral antithrombin and anti-xa agents with heparinized and oral anticoagulant treated patients : Pp-th-142 (2009) (2)
Plasma Nucleosomes Correlate with Markers of Inflammation and Thrombosis in Patients with Sepsis‐Associated Coagulopathy (2017) (2)
Surgical thrombectomy. (2013) (2)
Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patients. (1993) (2)
Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. (2004) (2)
Product Associated Variation in Generic Enoxaparin. Potential Clinical Implications (2011) (2)
A Multicenter Pilot Study to Estimate the Prevalence of Bovine and Human Coagulation Antibodies in the General US Population (2011) (2)
ProteinChip Array Profiling and Markers of Inflammation and Thrombin Generation in Plasma Samples from Lung Cancer Patients and Their Modulation by Chemotherapy with or without Warfarin Anticoagulation. (2007) (2)
Sulodexide for the extended treatment of venous thromboembolism. (2016) (2)
C3, A Promising Ultra Low Molecular Weight Glycosaminoglycan for the Treatment of Alzheimer’s Disease (2002) (2)
Restoration of Normal Prothrombin Time/International Normalized Ratio With Fresh Frozen Plasma in Hypocoagulable Patients (2016) (2)
Intermittent pneumatic compression and fibrinolysis: Description of a new model (1996) (2)
The Effect of a Novel Glycoprotein IIb/IIIa Antagonist, SR 121566A, on Platelet Aggregation and Activation in Rhesus Monkeys (2001) (2)
Procoagulant and inflammatory mediators in small cell lung carcinoma: Potential role in thromboembolic complications. (2011) (2)
Biomarker Profiling of Plasma Samples for Various Diseases Utilizing RANDOX Biochip Array Technology (2019) (2)
Acute Myocardial Infarction: Diagnosis and Management (1995) (2)
Apixaban to prevent venous thromboembolism after knee replacement (2010) (2)
Macroglobulinemia of Waldenström diagnosis and management. (1978) (2)
Interactions of Oversulfated Chondroitin Sulfate (OSCS) From Different Sources With Unfractionated Heparin (2012) (2)
Combined Modalities in Surgical Patients (2013) (2)
Comparative Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies (2019) (2)
Current perspectives in antithrombotic therapy (2001) (2)
Presence of asymmetric dimethylarginine gradients across high-grade lesions in patients with coronary artery disease (2007) (2)
Studies on a Novel Circulating Anticoagulant in a Female with Bleeding Diathesis (1977) (1)
Differential Activation of Prothrombin by Factor Xa, Ecarin and Taipan Venom as Studied by ProteinChip Array Profiling with Surface Enhanced Laser Desorption Ionization (SELDI) Analysis (2007) (1)
P-selectin in major depression: preliminary findings with venlafaxine treatment. (2010) (1)
Antithrombotic Agents in the Management of Sepsis. (2002) (1)
Comparative Antithrombotic and Bleeding Effects of Two U.S. Generic Enoxaparins (2012) (1)
Pre-Existence of Prothrombotic State in Patients with Atrial Fibrillation Despite Therapy with New and Traditional Anti-Coagulant Drugs (2015) (1)
Antithrombotics and thrombolytics in stroke. (2002) (1)
Absolute pharmacokinetics of heparin in primates. (2023) (1)
Dengue Fever and Thrombocytopenia: A Deadly Duo. (2006) (1)
Baseline Thrombin Generation Markers and Functional Antithrombin Levels in Sepsis Associated Coagulopathies Are Predictive of the Severity of Pathogenesis (2015) (1)
Novel Biomarkers and Subclinical Atherosclerosis (2011) (1)
Biomarkers of Hemostatic Activation and Inflammation Are Associated with Altered Coagulation Parameters in Sepsis Patients (2019) (1)
Effect Of Exercise On Platelet Function In Patients With Intermittent Claudication (1981) (1)
Immune-Mediated Activation Of Coagulation In Patients With Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (2013) (1)
Neutralization of the Anticoagulant and Anti‐Xa Effects of Fondaparinux and Idraparinux by a Novel Synthetic Antagonist. Pharmacologic Implications (2008) (1)
Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF-α. Interrelationship between Thrombogenesis and Inflammation (2019) (1)
Effect of Heparin and Its Derivatives On the Progression of Tumor Growth in Mouse Lewis Lung Carcinoma Model. (2012) (1)
Collagen Remodeling and Fatty Acid Regulation Biomarkers in Understanding the Molecular Pathogenesis of Atrial Fibrillation (2022) (1)
Tumor biology and pathology (2012) (1)
Relationship of Markers of Inflammation, Infection and Endothelial Function to Mortality and Severity of Coagulopathy in Patients with Sepsis-Associated DIC (2018) (1)
Tissue Factor Pathway Inhibitor Release is Specific for Heparin and Low Molecular Weight Heparins. Implications in the Management of Coronary Syndromes (1998) (1)
Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism (2022) (1)
Venous Disorders: Medical Management (2015) (1)
Antagonism of the Antithrombotic Effects of Heparin and Fraxiparine® in a Rat Model of Laser‐induced Thrombosis (1989) (1)
Epilogue: Anticoagulant management of patients undergoing interventional procedures (2007) (1)
Protein C depleted activated prothrombin complex neutralizes the bleeding associated with recombinant hirudin (1994) (1)
Cross Reactivity of Human Recombinant thrombin (Recothrombin) to Antibovine Thrombin Antibodies. Clinical Implications (2009) (1)
USP Potency Adjusted Bovine Mucosal Heparins (BMH) Are Comparable to Porcine Mucosal Heparin (PMH) at Equivalent Levels (2019) (1)
Tissue Factor Pathway Inhibitor is a Potent Inhibitor of Plasmin (1998) (1)
Biomarker profiling of bladder cancer patients undergoing radical cystectomy: Relevance of thrombotic and inflammatory processes. (2012) (1)
Role of PAI-1 and TAFI in the mediation of fibrinolytic deficit in cancer patients. (2004) (1)
The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19 (2022) (1)
Enoxaparin (E) and warfarin (W) differentially regulate tissue factor (TF), tissue factor pathway inhibitor (TFPI) and thrombin activatable fibrinolytic inhibitor (TAFI) in cancer patients with thrombosis (2005) (1)
The Effects of Aspirin and its Metabolites on Peripheral Blood Mononuclear cells and Human Retinal Pigment Epithelial Cells - Implications in the Pathophysiology of Age-Related Macular Degeneration. (2014) (1)
Abstract 1317: Anticoagulant Responses in Patients Receiving Low Molecular Weight Heparin Compared to Unfractionated Heparin for Transesophageal Echocardiography Guided Cardioversion of Atrial Fibrillation: Results from the Assessment of Cardioversion Using Transesophageal Echocardiography Randomize (2006) (1)
New development in anticoagulant and antithrombotic therapy: Are we on the right track? (2005) (1)
Despite Pharmaceutical Equivalence, Generic Versions of Enoxaparin May Differ in Their Pharmacodynamic Actions. Potential Clinical Implications (2012) (1)
Anti-Inflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Receptors. Experimental and Clinical Observations. (2006) (1)
Defibrotide does not cross‐react with HIT antibodies. Implications in the management of HIT (2006) (1)
Circulating Levels of Rivaroxaban Provide Different Results in Different Clot Based and Amidolytic Assays. a Study on Patients Treated with Two Different Dosages of Rivaroxaban (2014) (1)
Current trends in antithrombotic drug and device development. (1996) (1)
Extracellular Nucleosome Levels in the Etiopathogenesis of Sepsis Associated Coagulopathy (2016) (1)
Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients With Severe Coronary Artery Disease. The ROADMAP-CAD Study (2020) (1)
AVE5026: A New Hemisynthetic Ultra Low Molecular Weight Heparin with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity for Management of Cancer Associated Thrombosis (2008) (1)
Effect of Recombinant Lubricin on Human Blood Coagulation Parameters and Platelet Aggregation (2016) (1)
Thrombolytic Therapy (2013) (1)
Abstract 2219: Biochemical and Pharmacological Validation of the Antithrombotic Anticoagulant Potential of Fondaparinux, Enoxaparin and Otamixaban as it Impacts the Management of ACS (2007) (1)
Association between serum levels of pro-metalloproteinase 1, tissue inhibitor of metalloproteinases 1 and 2 and prevalent cardiovascular disease in a population-based study. (2013) (1)
Biomarker Profiling of Bladder Cancer Patients Undergoing Radical Cystectomy. Relevance of Thrombotic and Inflammatory Processes (2012) (1)
Protamine Sulfate Neutralization Profile of Various Dosages of Bovine, Ovine and Porcine UFHs and Their Depolymerized Derivatives in Non-Human Primates (2021) (1)
National Trends for Peripheral Artery Disease and End Stage Renal Disease From the National Inpatient Sample Database (2021) (1)
Differential Modulation of Cytokines by VEGF In End Stage Renal Disease (2010) (1)
Gender-based differences in hemostatic responses. (2012) (1)
Hepatic Disorders Contribute to Platelet Dysfunction (2021) (1)
Studies on the Inhibition of Glandular and Plasma Kallikreins by Derivatives of Low Molecular Weight Peptide Analogues of Bradykinin. (1979) (1)
Endogenous Glycosaminoglycans in Various Pathologic Plasma Samples as Measured by a Fluorescent Quenching Method (2022) (1)
Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates (2020) (1)
Hemostatic modulation with the liver dialysis device in humans with advanced liver disease. (2002) (1)
The Problem and the Need for Prevention (2013) (1)
Role of Platelet Activation in the Pathogenesis of Heart Failure in End-Stage Renal Disease Patients (2015) (1)
Coagulation Profiling of Human, Non‐human Primate, Pig, Dog, Rabbit, and Rat Plasma: Pharmacologic Implications (2006) (1)
SUBSTITUTED AZOPURINES PART 1, SYNTHESIS OF 8,8′-DIOXO-6,6′-AZOPURINE (1974) (1)
A Factor Xa Inhibitor Antidote (andexanet alfa) is Capable of Neutralizing the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin in a Comparable Manner as Protamine Sulfate (2019) (1)
Effect of purified poloxamer 188 and various dextrans on erythrocyte sedimentation rate in healthy subjects and patients with sickle cell disease (1139.6) (2013) (1)
Coagulant versus amidolytic properties of human and bovine thrombins: implications in standardization and diagnostic usage. (1986) (1)
Key Questions to be Answered (2013) (1)
Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa (2020) (1)
Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa (2022) (1)
Generic versions of low molecular weight heparins may not have the same safety–efficacy profile as the branded low molecular weight heparins in acute coronary syndromes (2011) (1)
A Higher Prevalence of HIT Antibodies in Patients May Be Due to Contaminated Heparin (2008) (1)
181 Interactions of ionic and non ionic contrast agents with thrombolytic agents (1988) (1)
Inhibition of Heparinase Depolymerization of Unfractionated Heparin by Sulfaminoheparosans (2007) (1)
Non-heparin glycosaminoglycan-derived drugs: a biochemical and pharmacologic perspective. (1991) (1)
A Comparison of the Anticoagulant Actions of Commercially Available Contrast Media (CM) (1977) (1)
Selection of a Suitable Rapid Turn Around and Sensitive Test for the Laboratory Monitoring of Newer Oral Anticoagulants, Rivaroxaban, Apixaban and Dabigatran, (2011) (1)
Factor Xa Inhibitors Can Be Differentiated in Xa, IIa and Microparticle Generation and Other Whole Blood Based Assays. (2007) (1)
Development of a Synthetic Heparin Pentasaccharide as an Antithrombotic Drug (2002) (1)
An Open Label, Non Randomized, Propspective Phase IV Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars In Healthy Volunteers. (2010) (1)
Tissue Factor Mediated Activation of Prothrombin Complex Concentrates (PCCs) Is Differently Inhibited by Dabigatran, Rivaroxaban and Apixaban. Potential Clinical Implications (2012) (1)
Comparing r-Tissue Factor and Mammalian Tissue Reagents for Prothrombin Time (1995) (1)
Contaminants Isolated From Recalled Heparin Are Not All the Same: Clinical Implications. (2009) (1)
Ticlopidine and Clopidogrel: Do They Have Direct Vascular Effects? (1997) (1)
Glanzmann’s Thrombasthenia Patients with No Mutations in Both the ITGA2B and ITGB3 Genes as Identified by Conformation Sensitive Gel Electrophoresis (CSGE) (2008) (1)
Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial (2022) (1)
Effect of erythropoietin stimulating agents on vascular endothelial growth factor levels in patients with end stage renal disease. (2016) (1)
Biomarkers of Platelet Activation and Their Prognostic Value in Patients in Sepsis Associated Coagulopathy (2017) (1)
Orthopedic Surgery and Trauma (2013) (1)
Potency Equated Porcine and Bovine Mucosal Heparin Are Bioequivalent in Terms of Biochemical and Pharmacological Effects (2019) (1)
Comparative ProteinChip Array Profiling of Human, Non‐human Primate, Pig, Dog, Rabbit, Rat, and Mice Plasma Using Surface Enhanced Laser Desorption Ionization (SELDI) Method (2006) (1)
Functional determination of antithrombin III in clinical samples and therapeutic concentrates. (1986) (1)
Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin). (1991) (1)
Clinical Nephrology - Lab methods and other markers (2012) (1)
Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin (2014) (1)
Neutralization of Hemorrhagic and Antithrombotic Activities of Heparins by a Novel Salicylamide Derivative (2009) (1)
DIFFERENTIAL NEUTRALIZATION OF UNFRACTIONATED HEPARIN (UH) AND LOW MOLECULAR WEIGHT HEPARINS (LMWHS) BY HUMAN PLATELET FACTOR FOUR (PF-4) (1987) (1)
Antithrombin and anti-Xa agents in the control of thrombogenesis. (2001) (1)
Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux (2019) (1)
Differential Effects of Unfractionated Heparin and Low-Molecular-Weight Heparins on Tissue Thromboplastin Inhibition Test (2000) (1)
Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version (2020) (1)
Suledoxide Mediated Inhibition of Tissue Factor Activation of Platelet. A Potential Mechanism for the Observed Therapeutic Effects in Diabetic Nephropathy (2008) (1)
Tissue Factor Pathway Inhibitor: Potential Implications in the Treatment of Cardiovascular Disorders (2002) (1)
AB3-1: Human atrial fibrillation is associated with endothelial dysfunction and oxidative stress (2006) (1)
Recombinant Factor VIIa–Mediated Activation of Prothrombin Complex Concentrates (2017) (1)
33 Heparin and related mucopolysaccharide interactions with thrombolytic and profibrinolytic agents: Pharmacologic studies in primates (1988) (1)
THE EFFECT OF BURN SIZE ON HEMOSTASIS (1991) (1)
IUA position statement on perioperative drug and hemostasis management in vascular surgery. (2022) (1)
COMPARISON OF OUTCOMES IN CATHETER-DIRECTED VERSUS ULTRASOUND-ASSISTED THROMBOLYSIS FOR TREATMENT OF PULMONARY EMBOLISM (2020) (1)
CONSENSUS Superficial vein thrombosis : a consensus statement (2012) (1)
Synovial Fluid Analysis in Patients with Osteoarthritis Requiring Total Joint Arthroplasty (2018) (1)
Utility of Blood Cellular Indices in the Risk Stratification of Patients Presenting with Acute Pulmonary Embolism (2021) (1)
Why differentiate low molecular weight heparins for venous thromboembolism? (2007) (1)
Cellular Indices and Outcome in Patients with Acute Venous Thromboembolism (2022) (1)
Inhibition of Heparinase I by Defibrotide: Potential Clinical Implications (2006) (1)
Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs. (2009) (1)
Public Perceptions of Current COVID-19 Vaccinations. Results of a Pilot Survey (2021) (1)
Critical Care Medical Patients (2013) (1)
Diagnostic strategy in heparin induced thrombocytopenia (2009) (1)
Identification of a unique plasma biomarker from patients undergoing total hip or knee replacement surgery utilizing protein chip array methods (2008) (1)
Contaminants in Heparins: Are All Facts Known? (2010) (1)
Increased blood levels of inflammatory cytokines CRP, TNF-α, CD40L, MCP-1 and Nitric Oxide in malignancy-associated thrombosis and their modulation by a low molecular weight heparin, Enoxaparin. (2004) (1)
The effect of enoxaparin on inflammatory and thrombotic mediators in cancer patients as studied using protein and biochip array approaches. (2011) (1)
Biochip Array Analysis of Various Mediators of Inflammation in Disseminated Intravascular Coagulation (2010) (1)
Down Regulation of Inflammatory Markers after Treatment with Topically Administered Mucopolysaccharide Polysulfate. (2004) (1)
DiagnosticEfficacyof Newer Synthetic-SubstratesMethodsfor Assessing CoagulationVariables:A Critical Overview (1983) (1)
Dysregulation of Inflammatory and Hemostatic Markers in Sepsis Associated Disseminated Intravascular Coagulation. (2012) (1)
Heparan sulphate inhibition of cell proliferation induced by TGFβ and PDGF (1993) (1)
Novel CT-derived parameter is associated with low cardiac index in acute pulmonary embolism. (2021) (1)
Isolation and Partial Characterization of a Novel Circulating Antithrombin (1979) (1)
Preclinical Atherosclerosis, Global Cardiovascular Risk and Cardiovascular Events (2012) (1)
Biochemical and pharmacological rationale for the use of newer oral anticoagulants in the long term management of heparin induced thrombocytopenia (LB526) (2014) (1)
Dysregulation of Biomarkers of Hemostatic Activation and Inflammatory Processes are Associated with Adverse Outcomes in Pulmonary Embolism (2022) (1)
Cross-Reactivity of Rabbit Anti-Bovine Thrombin IgGs with Human α-Thrombin and a Recombinant Version of Human Thrombin (Recothrom™). (2009) (1)
Antithrombin III assays. (1978) (1)
Reversal of new oral anticoagulants and personalized medicine. (2017) (1)
The irrelevance of International Normalized Ratio in the monitoring of anti-IIa and anti-Xa drugs (2003) (1)
Idarucizumab, a Specific Antidote for Dabigatran, Cross-Reacts with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds (2016) (1)
Liver Diseases Contribute to Functional Platelet Aggregation Defects (2020) (1)
Aspirin and its Metabolites Enhance the Expression of Vascular Endothelial Growth Factor in Retinal Pigment Epithelial Cell Cultures - Implications in the Pathophysiology of Age-Related Macular Degeneration (2015) (1)
Historical Overview of Glycosaminoglycans (GAGs) and their Potential Value in the Treatment of Alzheimer’s Disease (2002) (1)
Acute Coronary SyndromesCARDIAC MYOSIN BINDING PROTEIN-C: A NEW BIOMARKER IN PATIENTS WITH ACUTE CORONARY SYNDROME (2012) (1)
Management of Thrombotic Disorders (2014) (0)
Impact of LMWH and Specific Factor Xa Inhibitors, Apixaban and Fondaparinux, on Cancer Cell Biology and Procoagulant Properties of Cancer Microenvironment (2021) (0)
Molecular Pathogenesis of Bone Degenerative Disease and Associated Inflammatory Processes (2020) (0)
Glycosaminoglycans and Glycomimetics: Potential Role in the Management of Alzheimer’s Disease (2002) (0)
Effect of Diabetes Mellitus on Metabolic Biomarker Levels in Patients with End Stage Renal Disease or Undergoing Total Joint Arthroplasty (2015) (0)
Molecular Systems Network Predicts Sars-Cov-2 NSP3 and Orf6 Role in COVID-19 Related Thrombotic Events (2022) (0)
Pregnancy associated alterations of the inflammatory mediators, tissue factor pathway inhibitor and protein Z (2006) (0)
A Unique Biomarker Is Associated with the Prevalence of Functional Heparin Induced Thrombocytopenia (HIT) Associated Antibodies: Results from Proteomic (ProteinChip Array) Profiling of ELISA Positive HIT Plasma Samples. (2007) (0)
Quantification of von Willebrand Factor and von Willebrand Factor Propeptide in Patients with End Stage Renal Disease (2010) (0)
LPS‐INDUCED PLATELET‐MONOCYTE AGGREGATES RESULTS IN P‐SELECTIN/PSGL‐1 DEPENDENT SIGNAL TRANSDUCTION.: 41 (2001) (0)
Urinary Prothrombin Fragment 1 + 2 as an Endogenous Marker of Venous Thromboembolism (2019) (0)
Biochemical and pharmacological differentiation of dabigatran, apixaban and rivaroxaban (2013) (0)
INCREASED THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) LEVELS IN BURN INJURY.: 30 (2003) (0)
Fibrinokinetic Deficit in Chronic Kidney Disease and End Stage Renal Disease Patients Contributes to the Hemostatic Abnormalities (2008) (0)
Differential restoration of prothrombin time / INR in plasma from warfarin‐treated patients by various prothrombin complex concentrates (833.6) (2014) (0)
Antiplatelet Actions Of Low Molecular Weight Peptides And Their Derivatives (1981) (0)
Review paper The role of sulodexide in chronic venous insufficiency (2014) (0)
Biomarkers of Hemostatic Dysregulation, Inflammation, and Infection in Patients Diagnosed with Sepsis Associated Coagulopathy (2015) (0)
Impact of Pulmonary Embolism Response Team on Anticoagulation Prescribing Patterns in Patients With Acute Pulmonary Embolism (2020) (0)
Abstract 17293: Functional Outcomes After Acute Pulmonary Embolism (2018) (0)
Diff erences in pharmacokinetic behaviour of branded enoxaparin and a US generic version in a non-human primate model (2015) (0)
Upregulation of Inflammatory Biomarkers in Pulmonary Embolism as Studied by a Biochip‐Array Profiling Approach (2020) (0)
Upregulation of Myeloperoxidase in End Stage Renal Disease and Its Modulation by Hemodialysis. A Paradoxical Paradigm. (2006) (0)
Decreased Thrombin Generation Potential in Lymphoma Patients is associated with Increased D‐dimer, CRP, vWF and TNF‐α. Interrelationship between Thrombogenesis and Inflammation (2020) (0)
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly diagnosed chemotherapy Naïve Patients with Multiple Myeloma at Risk for Cancer-associated Thrombosis. The Observational ROADMAP-CAT-MM Study (2018) (0)
THE EFFECT OF MOLECULAR WEIGHT ON THE RELATIVE BIOAVAILABILITY OF HEPARIN (1987) (0)
Coagulation profiling of class B vendor cats with reference to serine protease inhibitors (2009) (0)
Protein Chip Array Profiling of Molecular Variants of Hirudins Using Surface Enhanced Laser Desorption Ionization (SELDI) Technique (2011) (0)
DECREASED LEVELS OF THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) IN SEPSIS.: 106 (2004) (0)
Dysregulation Of Thrombotic and Hemostatic Factors In End Stage Renal Disease (2013) (0)
Proteomic Analysis of Plasma and Mucosal Samples from Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (2013) (0)
Differential Prevalence of Anti-Heparin-Platelet Factor 4 Antibodies In Elderly Patients with Acute Hip Fracture Undergoing Orthopaedic Surgery and Anticoagulated with Unfractionated Heparin and Enoxaparin (2010) (0)
Potency Adjusted Bovine Heparin is Comparable to Porcine Heparin in Patients Undergoing Open Heart Surgery (2019) (0)
Biological and Pharmacological Profiling of Pentosan Polysulfate (PPS) in Comparison to Heparin and its Relative Neutralization by Protamine Sulfate (2020) (0)
PREVALENCE AND OUTCOME OF ACUTE PULMONARY EMBOLISM IN PATIENTS WITH A HISTORY OF INFLAMMATORY BOWEL DISEASE (2023) (0)
Oxidative Stress Biomarkers in Patients with End Stage Renal Disease (2022) (0)
USP Potency Adjusted Bovine Mucosal Heparins are Comparable to Porcine Mucosal Heparin and May be Interchangeable for Anticoagulation (2022) (0)
Tissue factor pathway inhibitor release is specific for heparins Implications in the management of cardiovascular syndromes (1998) (0)
NewPerspectives inCoagulation Testing (1980) (0)
Development of Prothrombinase Induced Clotting Time (Pefakit ®, PiCT) Assay and its Validation in the Monitoring of Anti-Xa and Anti-FIIa Drugs. (2004) (0)
An Update on Low‐Molecular‐Weight Heparins (2014) (0)
Abstract TP411: Biomarker Profiling of Neurovascular Diseases in Patients With Stage 5 Chronic Kidney Disease (2018) (0)
The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients (2021) (0)
Biochip Array Profiling of Inflammatory Cytokines and Growth Factors In End-Stage Renal Disease: Hematological Implications? (2010) (0)
POTENTIAL ROLE OF ADHESION MOLECULES P, E, AND L-SELECTINS IN THE PATHOGENESIS OF PULMONARY EMBOLISM (2020) (0)
Symptom Duration Is Positively Correlated with Factor XIIIa Activity in Acute Pulmonary Embolism (2018) (0)
Differential Augmentation of Thrombin Generation by Andexanet Alfa in Lymphoma Patients (2020) (0)
Comparative Studies On Heparin Contaminant Interactions with Normals, Liver Disease, Heparin Treated and Oral Anticoagulant Treated Patients Plasma. (2009) (0)
Platelet Activation in End-Stage Renal Disease Is Mediated By Extracellular Nucleosomes That Originate from White Blood Cells (2016) (0)
ANTI-HUMAN PLATELET FACTOR 4-HEPARIN ANTIBODIES ARE CAPABLE OF ACTIVATING PRIMATE PLATELETS AS MEASURED BY 14C-SEROTONIN RELEASE (1999) (0)
Profiling of Inflammatory Biomarkers and Coagulation Factors in End‐Stage Renal Disease (2020) (0)
Abstract (2003) (0)
Recombinant Thrombomodulin Inhibits Tissue Factor Mediated Thrombin Generation in Blood Plasma and Is Modulated By Prothrombin Complex Concentrates (2015) (0)
Nitric Oxide and Asymmetric Dimethlyarginine Levels in Malignancy Associated Thrombosis and Their Modulaiton by Anticoagulants. (2006) (0)
The Proteomic Profile of Normal and Keratoconic Epithelial and Stromal Layers by Proteinchip using Seldi-Tof-Mass Spectrometry (2012) (0)
FP327ELEVATED LEVELS OF EXTRACELLULAR NUCLEOSOMES, BIOMARKERS OF CELL DEATH, IN STAGE 5 CHRONIC KIDNEY HEMODIALYSIS (CKD5-HD) ARE INDEPENDENT OF CIRCULATING TISSUE FACTOR MICROPARTICLE COMPLEX (2018) (0)
Prevalence of Non‐Specific Cross‐Reactive Epitopes to Bovine Factor Va Light Chain Fragments in Normal and Patient Plasma (2007) (0)
FLOW CYTOMETRIC STUDIES ON DRUG INTERACTIONS BETWEEN ANTI‐XA, ANTI‐IIA, AND ANTIPLATELET AGENTS (2006) (0)
Effect of Heparin and Low Molecular Weight Heparin on the Regulation of Microparticle in Atrial Fibrillation (2008) (0)
Clinical and Experimental Evaluation of the Interaction of Anticoagulant Drugs with Radiologic Contrast Media (1979) (0)
The Impact of Glycemic Control in Thrombo-Inflammatory Biomarkers in Diabetic Pulmonary Embolism Patients (2022) (0)
126: Pregnancy associated alterations of the inflammatory mediators and protein zmediators and protein Z (2007) (0)
Validation of the Bioequivalence of USP Potency Adjusted Porcine, Ovine, and Bovine Heparins (2020) (0)
Thrombotic Biomarker Profiling Of Plasma Samples From Patients Undergoing Bypass Surgery Using Protein Chip Array (2013) (0)
IMPACT OF OBESITY ON TIME-TO-THERAPEUTIC HEPARIN IN ACUTE SUBMASSIVE PULMONARY EMBOLISM (2020) (0)
Further Studies on the Isolation and Characterization of Heparin Contaminants Isolated From Recalled Batches of Unfractionated Heparin (2012) (0)
Angiogenic Vascular Endothelial Growth Factor (VEGF) Levels Significantly Correlate to Systemic Inflammatory Response Index (SIRI) Measures in Patients with Treatment-Resistant Bipolar Depression Disorder (TRBDD) (2022) (0)
Generic and Branded Versions of Argatroban Exhibit Differential Anticoagulant Effects In Whole Blood, Plasma Based Assays and Thrombin Generation Assays (2010) (0)
Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma (2019) (0)
Regulation of Cortisol in Patients Undergoing Total Joint Arthoplasty (2021) (0)
Discordance between the 1st and 2nd low molecular weight heparin (LMWH) standards. Implications for dosing (2005) (0)
USP Potency Equated Enriched Bovine and Porcine Mucosal Heparins Exhibit Comparable Biochemical and Pharmacological Effects (2019) (0)
New Aspects on Hirudin: 1st International Symposium on Hirudin, Frankfurt, June 1989: Proceedings (1991) (0)
1524 – PHARMACOLOGICAL AND BIOCHEMICAL STUDIES ON A NON-HEP ARIN CIRCULATING ANTICOAGULANT IN A FEMALE (1977) (0)
Thrombo‐inflammatory Biomarkers in Patients with End‐Stage Renal Disease (2022) (0)
P161 PLASMA INFLAMMATORY MARKERS AND SUBCLINICAL ATHEROSCLEROSIS (2010) (0)
Baseline and Serial Microparticle Concentration Analysis in Elderly Patients with Acute Hip Fracture Treated with Heparins (2010) (0)
RELATIONSHIP BETWEEN ATRIAL FIBRILLATION AND ANGIOPOIETIN-2 ELEVATION REMAINS SIGNIFICANT FOLLOWING 1-YEAR INTERVAL (2020) (0)
Argatroban and Lepirudin: Clinical Trials to Clinical Practice (2005) (0)
Subject Index, Vol. 21, 1991 (1991) (0)
Comparative Studies on the Anticoagulant Actions of Recombinant Thrombomodulin and Heparin and Their Neutralization By FEIBA As Measured By Thromboelastography (2016) (0)
Increased Extracellular Nucleosome Levels and Microparticles in Atrial Fibrillation Patients Compared to the Age-Matched Normal Population (2016) (0)
Subject Index, Vol. 21, 1991 (1991) (0)
Development and Implementation of an Online Global Pharmacovigilance Certificate Program During the COVID-19 Pandemic (2022) (0)
Identification of Unique Biomarkers in Sepsis Associated Coagulopathy (2011) (0)
Elevated salivary cortisol predicts response to adjunctive immune modulation in treatment-resistant bipolar depression (2021) (0)
Prevalence of Cross Reactive Epitopes to Bovine Factor Va Light Chain Fragments in Normal and Patients Plasma. (2006) (0)
HEMODIALYSIS DOWN REGULATES THE INFLAMMATORY MEDIATORS IN PATIENTS WITH END STAGE RENAL DISEASE (2007) (0)
Relative Immunologic Potential of Bovine Prothrombin and Purified Thrombins (2008) (0)
Expression of osteopontin and markers of inflammation in patients with hepatocellular cellular carcinoma. (2015) (0)
Protamine Sulfate Neutralization of Bovine and Porcine Heparins: Developmental Implications. (2017) (0)
Anticoagulation of Heparin Compromised Population with a Direct Synthetic Anti Xa agent Otamixaban (2011) (0)
Differential Prevalence of Anti‐Heparin PF4 Immunoglobulin Subtypes in Patients Treated with Reviparin, Enoxaparin, and Certoparin. Implications in HIT Pathogenesis. (2008) (0)
Nitric oxide and asymmetric dimethylarginine and CD 40 ligand levels in malignancy associated thrombosis and their modulation by anticoagulants (2007) (0)
Antiinflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Inhibitors. Experimental and Clinical Observations (2007) (0)
Dysregulation of Hemostatic Biomarkers, Inflammatory Biomarkers, and Alteration of Cellular Indices As Predictors of Adverse Outcomes in Pulmonary Embolism Patients (2019) (0)
The Role of Blood Cellular Indices in Diabetic Pulmonary Embolism Patients in Predicting Adverse Outcomes (2022) (0)
THE PARADOX OF CHOICE: THERAPEUTIC DECISION MAKING WITH COMPLEX PULMONARY EMBOLI (2019) (0)
774 DO PLASMA TRIGYCERIDE (TG) LEVELS MODULATE HCV REPLICATION RATES (2010) (0)
Harry L. Messmore, Jr., MD (1922–2011) (2012) (0)
ENDOGENOUS DYSREGULATION OF THROMBOINFLAMMATORY BIOMARKERS IN END-STAGE RENAL DISEASE, AND THEIR AMPLIFICATION BY HEART FAILURE (2023) (0)
Cellular and Functional Characterization of Microparticles in Sepsis-Associated Coagulopathy (2015) (0)
Low Molecular Weight Heparin’s Mechanism of Action: Pharmacologic Profile and Product Differentiation (1998) (0)
Enoxaparins Derived from Ovine (Sheep) Tissues are Biosimilar to Branded Enoxaparin of Porcine (Pig) Origin (2018) (0)
Recombinant Thrombomodulin Does Not Cross React with Anti‐heparin Platelet Factor 4 Antibodies. Potential Implication in the Anticoagulant Management of Heparin Induced Thrombocytopenia Patients (2007) (0)
Unfractionated heparin, but not a low-molecular-weight heparin (Clivarin), mediates differential generation of anti-heparin-PF4 antibodies in orthopedic surgery patients: Pathophysiologic and pharmacologic implications (2003) (0)
Comparison of Branded Enoxaparin (Lovenox) and a Biosimilar Version of Enoxaparin (Fibrinox) (2010) (0)
Molecular and cellular pathogenesis of endothelial lining in atrial fibrillation (2022) (0)
Compositional differences in commercial available prothrombin complex concentrates and their activation by tissue factor (2013) (0)
SUBCUTANEOUS PHARMACOKINETICS/PHARMACODYNAMICS OF A LOW MOLECULAR WEIGHT DERIVATIVE (RD 11885) AND UNFRACTIONATED HEPARIN (PM 16885) IN PRIMATES (1987) (0)
The Effect Of PF-4 Peptide Analogues On Platelet Activation And Release (1981) (0)
Elevated Matrix Metalloproteinase 9 in Treatment Resistant Bipolar Depression (2022) (0)
Suppression of Markers of Thrombin Generation and Inflammation in Patients Receiving Low Molecular Weight Heparin Compared to Unfractionated Heparin for TEE-Guided Cardioversion of Atrial Fibrillation. (2007) (0)
Hyperhomocysteinemia in Cancer Patients with Thrombosis is Not Associated With Methylene Tetrahydrofolate Reductase Gene Mutations and Can Be Down Regulated by Low Molecular Weight Heparin Treatment (2006) (0)
Defibrotide Interactions with Newer Oral Anticoagulants and Antithrombotic Agents (2012) (0)
Pharmacodynamic Differences in the Two Generic Brands of Enoxaparin (2011) (0)
Pharmacological Treatment of Venous Disorders (2014) (0)
Elevated Circulating CD40‐L in Atrial Fibrillation and Its Modulation by Ablation (2017) (0)
RETROSPECTIVE ANALYSIS OF THROMBOGENIC BIOMARKERS IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH NOVEL ORAL ANTICOAGULANTS (2017) (0)
LOW MOLECULAR WEIGHT HEPARIN AMELIORATES THE CARDIOPULMONARY AND PATHOMORPHOLOGIC EFFECTS OF ENDOTOXIN.: 180 (1996) (0)
A Comparison Of Hemostatic and Inflammatory Markers In Overt and Non-Overt DIC (2013) (0)
Quantitative TFPI Antigen Release and Functionality After Intravenous Administration of Heparins Sourced From Various Species in Non‐human Primates (2022) (0)
Increased Biomarkers of Metabolic Syndrome in Total Joint Arthoplasty Patients (2015) (0)
Neutralization of Unfractionated Heparin (UFH) and a Bioengineered Heparin Dodecasccharide (12‐mer) by Protamine Sulfate (2017) (0)
Continuous Subcutaneous Heparin Infusion During Pregnancy In A Patient With A Prosthetic Mitral Valve. Clinical And Laboratory Consideration (1981) (0)
Comparative Studies on An Anti-Xa Enriched Ultra Low Molecular Weight Heparin with Bemiparin (2010) (0)
Comparative effects of direct thrombin inhibitory peptides and heparin in global and biochemically defined non-plasmatic systems (1993) (0)
DIAGNOSTIC COMPLEXITIES OF LEFT ATRIAL MASSES AND THE VALUE OF A PULMONARY EMBOLISM RESPONSE TEAM (2020) (0)
New Indications for Low-Molecular- Weight Heparins (2002) (0)
Persistent Prothrombotic State in Atrial Fibrillation Despite Use of Novel Oral Anti-Coagulants (2016) (0)
496. Index of Peripheral Inflammation is Associated With Arterial Stiffness in Treatment-Resistant Bipolar Depression (TRBDD) (2023) (0)
C-20 | CT Predictors of Acute Decompensation and ICU Admission in Acute Pulmonary Embolism (2022) (0)
Defibrotide Augments the Anticoagulant Actions of Heparin and Low Molecular Weight Heparins (2008) (0)
Correlation of Nucleosomes, MMP‐9, and IL‐1α with Relation to Neutrophil Activation in Patients with Atrial Fibrillation (2017) (0)
Activation Markers of Thrombogenesis and Endothelial Dysfunction In End-Stage Renal Disease (2010) (0)
Comparative hemmorhagic studies on dabigatran, apixaban and rivaroxaban in a rat‐tail bleeding model (2013) (0)
Professor Hans Klaus Breddin (1928-2006): A World-Class Physician, Mentor, and Friend (2007) (0)
SP306UP-REGULATION OF INFLAMMATORY MEDIATORS AND MARKERS OF METABOLIC DERAIGNMENT IN END STAGE RENAL DISEASE AS STUDIED BY BIOCHIP ARRAY ANALYSIS (2015) (0)
13th Annual meeting of the European Venous Forum, Thursday 28 June–Saturday 30 June 2012, Florence, Italy (2012) (0)
In Vivo and Ex Vivo Thrombin Generation in Noncomorbid Patients with Suspected Deep Venous Thrombosis (2019) (0)
Dabigatran Neutralizing Antobody, Idarucizumab, Exhibits Procoagulant and Platelet Activation Responses in Whole Blood. Potential Clinical Implications (2016) (0)
Comparative Studies Of Purified Poloxamer 188 Using ClotBased and Viscoelastic Measurements Of Coagulation (2013) (0)
[Low molecular weight heparin fractions. Comparative preclinical study of various parameters]. (1987) (0)
DIFFERENTIAL MODULATION OF COAGULATION AND FIBRINOLYSIS BY NEW ORAL ANTICOAGULANTS. PHARMACOLOGIC IMPLICATIONS (2012) (0)
841 – STUDIES ON THE ANTAGONISM OF THE RESPONSE OF SMOOTH MUSCLE TO BRADYKININ BY LOW MOLECULAR WEIGHT SYNTHETIC TRIPEPTIDE ANALOGUES OF BRADYKININ (1978) (0)
Upregulation of monocyte chemotactic protein-1 and CD40 ligand in cancer patients and their modulation by subcutaneous enoxaparin-results from the ONCENOX study (2004) (0)
Markers of Thrombogenesis Activation and Endothelial Dysfunction in End Stage Renal Disease (2011) (0)
Argatroban is Capable of Passing Through the Blood Brain Barrier. Potential Implications in the Management of Thrombotic Stroke (2007) (0)
Differential Pharmacokinetics of Sulfaminoheparosans (SAHs) and Heparins In Vivo in Rats : Pharmacological Implications (2006) (0)
Regulation of Microparticles and Adhesion Molecules in Pregnancy. Diagnostic and Pathophysiologic Implications. (2007) (0)
Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Antiheparin Platelet Factor 4 Antibodies as Studied in Platelet Aggregation Assays (2020) (0)
Differential Effects of Dabigatran, Rivaroxaban, Apixaban, Edoxaban and Betrixaban on Fibrinokinetics and their Modulation by FEIBA (2019) (0)
Cross Reactivity of Natural Hirudin Compared to the Recombinant Hirudins with Sheep Anti Hirudin Antibody (2011) (0)
BIOMARKER PROFILE OF ENDOTHELIAL FUNCTION IN PATIENTS WITH END STAGE RENAL DISEASE (2021) (0)
Safety and efficacy of currently used COVID‐19 vaccines: Results of a pilot survey (2022) (0)
OLD DOG, NEW TRICK: NOVEL CT-DERIVED PARAMETER IS ASSOCIATED WITH LOW CARDIAC INDEX IN ACUTE PULMONARY EMBOLISM (2020) (0)
ORIGINAL ARTICLE Singlet oxygen ( 1 O 2 ) Inactivates Plasmatic Free and Complexed a 2 -Macroglobulin (2000) (0)
Augmentation of the Anticoagulant Effects of Heparin By a Tri-Block Polymer MST-188 (2014) (0)
SP286BIOMARKER ANALYSIS OF VASCULAR OUTCOMES IN END STAGE RENAL DISEASE (2015) (0)
Thrombotic and Inflammatory Mediators in Cancer Patients Are Downregulated by Enoxaparin. Biochip and Protein Array Analysis (2011) (0)
Tissue Factor Mediated Activation of Proteases in Purified Prothrombin Complex Concentrates is Inhibited by Mucosopolysaccharide Polysulfate. Results from the Studies on Proteinchip Array using SELDI (2006) (0)
MON-316 CALCIUM REGULATORY AND BONE TURNOVER BIOMARKER LEVELS DO NOT INDICATE PRESENCE OF OSTEOPOROSIS AND OSTEOPENIA IN END STAGE RENAL DISEASE (2019) (0)
MOLECULAR MARKERS OF COAGULATION, FIBRINOLYSIS AND VASCULAR ACTIVATION IN TRAUMA PATIENTS. (1995) (0)
Computed Tomography Detection Of Hemorrhagic And Thrombotic Disorders (1981) (0)
Anticoagulant profiling of a Generic Enoxaparin and its comparison with its Branded version (2017) (0)
Prevalence of Heparin Platelet Factor 4 Antibody in Hip Fracture Patients Undergoing Orthopaedic Surgery Treated with Heparin versus Enoxaparin and Their Relevance to Serum Amyloid A (2010) (0)
Role of defibrotide in immunoregulation of sheep red cell sensitization in a rat model. (1988) (0)
Tissue Factor Positive Extracellular Vesicles and Risk of Thromboembolism in Diffuse Large B-Cell Lymphoma: A Prospective Exploratory Study (2022) (0)
Generic versions of argatroban can be differentiated from branded argatroban using a thrombin generation assay (TGA) (2009) (0)
Physiology of Hemostasis (2016) (0)
Variations in the Circulating Heparin Levels During Maintenance Hemodialysis in End Stage Renal Disease Patients (2012) (0)
Ovine Mucosal Enoxaparin Exhibit Comparable Pharmacokinetic Profiles to Porcine Mucosal Enoxaparin (2019) (0)
Prevalence of Anti‐human and Anti‐bovine Thrombin Antibodies in Healthy Individuals and Patients with End Stage Renal Disease (2007) (0)
Low Molecular Weight Heparins : Basic and Applied Considerations (2004) (0)
Thrombin Generation Assessment in Platelet Rich Plasma Offers Additional Criteria for Low Molecular Weight Heparin Antithrombotic Fingerprint Characterization. (2009) (0)
Hematological Complications in Obstetrics, Pregnancy, and Gynecology: Low molecular weight heparins in pregnancy (2006) (0)
DYSREGULATION OF INFLAMMATORY AND FIBRINOLYTIC BIOMARKERS IN PULMONARY EMBOLISM SUBCATEGORIES (2020) (0)
339: Therapeutic aPTT With Heparin Within 24 Hours Improves Mortality in Acute Pulmonary Embolism (2020) (0)
Structural and molecular heterogeneity in low molecular weight heparins! Impact on clinical applications and standardization (1990) (0)
Glycosaminoglycans for the treatment of emotional disorders (2004) (0)
INTERPLAY OF ADHESION MOLECULES WITH THROMBO-INFLAMMATORY PROCESSES IN PULMONARY EMBOLISM (2023) (0)
MODULATORY EFFECT OF SERINE PROTEASES AND RELATED ENZYMES ON ISOLATED SMOOTH MUSCLE PREPARATIONS (1987) (0)
Subject Index, Vol. 22, 1992 (1992) (0)
A serotonin and beta HCG-producing islet cell carcinoma associated with focal nodular hyperplasia of the liver. (1983) (0)
Different Sources of Over‐Sulfated Chondroitin Sulfate (OSCS) May Produce Differential Interactions with Heparins (2010) (0)
Oxide and Arginine Metabolism in Depression: Effect of a Serotonin-Norepinephrine Reuptake Inhibitor (2009) (0)
201. Inflammation and endothelial dysfunction in depression and anxiety disorders (2011) (0)
Differences in the native and heparinase I digestion profiles of a generic enoxaparin: Pharmacologic implications (2006) (0)
Population Based Differences in the Anticoagulant and Antiprotease Responses of Newer and Oral Anticoagulant Drugs (2012) (0)
Pharmacoequivalence of Enoxaparin and Contaminated Enoxaparin (2008) (0)
Evaluation of "Statsep," a semiautomated device to prepare plasma samples for coagulation analysis. (1983) (0)
COMPARATIVE PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED HEPARIN (HEP) AND A LOW MOLECULAR WEIGHT HEPARIN (LMWH) AS STUDIED BY AN EX VIVO FIBRINOPEPTIDE A (FPA) GENERATION TEST (1987) (0)
Variation in the thrombin activatable fibrinolytic inhibitor (TAFI) modulation by heparin: Therapeutic implications. (2003) (0)
Resourcing of Porcine Unfractionated and Low‐Molecular Weight Heparins from Ovine, and Bovine Sources (2020) (0)
Prevalence of heparin induced thrombocytopenia antibodies in cancer patients treated with a low molecular weight heparin (2008) (0)
Compositional Differences in the Oligosaccharide Components of Generic Versions of Enoxaparin and Dalteparin. (2007) (0)
Heparins Derived from Ovine (Sheep) Mucosa are Interchangeable to their Porcine (Pig) Counterparts (2018) (0)
Molecular and Functional Heterogeneity in Contaminants Isolated from Recalled Heparin. Impact on Anticoagulation and Potential Adverse Reactions (2008) (0)
Current aspects in Chronic Venous Disease (2014) (0)
Bovine and Porcine Mucosal Heparins Exhibit Similar Biologic Profiles (2015) (0)
Tissue factor and tissue pathway inhibitor: A link between a hemostatic disorder and preterm PROM? (2006) (0)
Abstracts of a Symposium on Heparin and Related Substances (1985) (0)
Recombinant Factor VIIa (rFVIIa) Mediated Activation of Prothrombin Complex Concentrates (PCCs). Studies on the Comparison of Novoseven with a Biosimilar Product (2014) (0)
List of Contributors (2019) (0)
Functional Microparticles Are up Regulated in Patients with Anti-Heparin/Platelet Factor 4 Antibodies: A Potential Mechanism of Thrombogenesis in the Heparin-Induced Thrombocytopenia Syndrome. (2007) (0)
Tissue Factor Pathway Inhibitor (TFPI) release by bovine, ovine and porcine unfractionated heparins in primates. Comparative studies at mass and potency adjusted intravenous dosing (2020) (0)
Extrinsic and common coagulation pathway profiling in TJA patients (2017) (0)
Increased prevalence of Anti‐Heparin Platelet factor 4 antibodies in patients with sepsis associated Disseminated Intravascular Coagulation (2011) (0)
Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncology. (2004) (0)
Comparative Study on the Anticoagulant Effects of Low Molecular Weight Heparins as Measured by Whole Blood Act, Anti-Xa and a Newly Developed Prothrombinase Induced Clotting Time (PiCT) Assay. (2005) (0)
Biochemical and Pharmacologic Profiling of a Novel Dual Acting Antithrombin Agent with Antiprotease and Antiplatelet Actions. Hematologic Implications. (2005) (0)
Bridging the diabetic microvascular and macrovascular gap in peripheral arterial disease. (2022) (0)
Functional Restoration of Platelets by Tri‐block Polymer (Vepoloaxmer) as Studied in Agonist Induced Platelet Aggregation Studies (2016) (0)
Computerized Axial Tomographic (CAT) Diagnosis Of Vascular Thrombosis And Patency Of Aorto-Coronary Bypass Graft (1981) (0)
Heparin-induced anti-platelet antibodies in very low birth-weight infants (2003) (0)
Preterm labor leading to preterm delivery in the absence of inflammation/infection is associated with low maternal plasma protein Z concentrations (2005) (0)
Decreased Immunogenicity of Purified Topical Bovine Thrombin Preparations. (2009) (0)
Pharmacodynamic Differences of An Anti-Xa Enriched Low Molecular Weight Heparin, AVE 5026 in Comparison to Enoxaparin and Unfractionated Heparin. (2009) (0)
The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients (2023) (0)
In Vitro and in Vivo Antithrombotic Effect of a Collagen-Derived Octapeptide (1987) (0)
Comparative studies on the antithrombin potency of various thrombin inhibitors, as determined by using an amidolytic method. (1996) (0)
Preeclampsia is associated with low concentrations of the novel regulatory factor of coagulation: Protein Z (2005) (0)
Pharmacology of Synthetic and Biotechnology-Derived Homologues and Analogues of Heparin (1995) (0)
Urologic Surgery (2013) (0)
UPREGULATION OF PLASMA MYELOPEROXIDASE AND MICROPARTICLES ENHANCE THROMBIN GENERATION IN ACUTE CORONARY SYNDROMES (2012) (0)
ANGIOPOIETIN-2 IS A POWERFUL PREDICTOR OF SEVERITY OF ILLNESS, RIGHT VENTRICULAR DYSFUNCTION AND IN HOSPITAL MORTALITY IN ACUTE PULMONARY EMBOLISM (2021) (0)
Molecular heterogeneity in low molecular weight heparins (1988) (0)
Branded Enoxaparin Versus Biosimilars in Healthy Volunteers An Open Label , Non-randomized , Prospective Clinical Trial Evaluating the Immunogenicity of (2010) (0)
A Generic Version of Recombinant FVIIa Is Similar to the Branded Product (NovoSeven) (2015) (0)
The Potential Role of Ferritin in Relation to Inflammatory and Metabolic Syndrome Biomarkers in Patients Undergoing Total Joint Arthroplasty of the Hip or Knee (2015) (0)
427: Regulation of microparticles and adhesion molecules in pregnancy. Diagnostic and pathophysiologic implications (2007) (0)
MOLECULAR MASKERS OF HEMOSTASIS FOLLOWING MAJOR INJURY: EFFECT OF THERAPY WITH INTERFERON-GAMMA (1994) (0)
Comparative Pharmacokinetic Profile of Three Batches of Ovine Enoxaparin and One Batch of Branded Enoxaparin (2018) (0)
Glycosaminoglycans having an average molecular weight equal to 2,400 d acts altrattamento of senile dementia (1999) (0)
Abstract 5200: Role of MLK3 in breast cancer cell migration and metastasis (2010) (0)
The Inter-Relationship between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Early-Stage Lung Cancer Patients (2022) (0)
Protease Generation by Chondroitin Sulfate, Semisynthetic OSCS Preparations and Contaminants Isolated From Heparin. (2009) (0)
Decreased Thrombin Generation Potential Is Associated with Increased Thrombin Generation Markers in Sepsis Associated Coagulopathy (2018) (0)
Should Generic Versions of Low Molecular Weight Heparins Be Considered As Generic or Biosimilar Drugs. A Regulatory Dilemma (2011) (0)
111. Stress, autonomic nervous system imbalance and psychopathology (2011) (0)
Species variation in the heparin contaminant mediated generation of kallikrein (2009) (0)
USP referenced potency evaluation of bovine heparins utilizing currently available assays (2017) (0)
Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study (2022) (0)
Coagulation profiling of random-source cats. (2010) (0)
Title Page / Table of Contents, Vol. 18, Supplement 3, 1988 (1988) (0)
PRE-CLINICAL FINDINGS OF A NOVEL THERAPEUTIC VACCINE TO LIMIT THE PROGRESSION OF CARDIOVASCULAR DISEASE: ATHEROVAX™ (2023) (0)
Comparative studies on the effect of heparins, oral anticoagulant, anti-Xa and anti-IIa drugs on thrombin activatable fibrinolytic inhibitor as measured by a functional assay (Pefakit (R) TAFI). Implications on endogenous fibrinolysis. (2003) (0)
Generic Low Molecular Weight Heparins : Where Do We Stand ? (2007) (0)
A symposium : low-molecular-weight heparins in arterial thrombosis : managing cardiovascular disorders (1998) (0)
Predictive Value of Cellular Blood Indices for All-Cause Mortality in Acute Pulmonary Embolism (2019) (0)
Heparinox, a generic version of low molecular weight heparin enoxaparin, is bioequivalent to the branded version (2020) (0)
An update on new anticoagulant drugs (2009) (0)
Thrombin Activatable Fibrinolytic Inhibitor Modulation in Heparin Supplemented Plasma: Clinical Considerations. (2004) (0)
Relevance of laboratory parameters to the clinical efficacy of Fraxiparin (1991) (0)
Inhibition of bradykinin-induced contraction of isolated smooth muscle tissue preparations by oligopeptide thiobenzyl ester substrates for serine proteases. (1983) (0)
Potential Role of ADAMTS13/FXI Complexes in the Pathogenesis of End Stage Renal Disease. (2005) (0)
Elevated Levels of Circulating Microparticles in Disseminated Intravascular Coagulation and Their Impact on the Inflammatory Process (2010) (0)
UPREGULATION OF MICROPARTICLES IN HEPARIN INDUCED THROMBOCYTOPENIA (HIT) AND IT'S MODULATION BY ARGATROBAN (2007) (0)
Biomarkers of Inflammation and Thrombosis in Patients Undergoing Total Joint Replacement (2021) (0)
Comparative Studies On Branded Enoxaparin and a US Generic Version of Enoxaparin. (2012) (0)
A Comparison of Mass and Potency Equated Bovine and Porcine Heparins (2020) (0)
Inhibition of Thrombin Generation: An Additional Biological Criterion for the Evaluation of the Anticoagulant Mechanism of Action of Generic LMWHs (2010) (0)
Upregulation of Von Willebrand Factor, Von Wilelbrand Factor Propeptide, and ADMATS-13 In End-Stage Renal Disease (2010) (0)
Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis (2019) (0)
STUDIES ON THE ANTITHROMBOTIC ACTIONS OF A COLLAGEN PEPTIDE IN A DEFINED MODEL OF VENOUS THROMBOSIS (1987) (0)
PREDICTORS OF LOW CARDIAC INDEX IN SUBMASSIVE PULMONARY EMBOLISM (2019) (0)
Biologic Potency Variation Among Bovine, Ovine and Porcine Heparins May be Due to their Differential Affinity to Antithrombin (2016) (0)
Synthetic, Organic Compound Poloxamer-188 Potentiates Action of Heparin and Tissue Plasminogen Activator (2015) (0)
Tissue factor mediated generation of thrombin in prothrombin complexes is inhibited by anti‐Xa based parenteral and oral agents but not by parenteral and oral antithrombin agents. Results from proteomic profiling using protein chip arrays (2012) (0)
A comparison of the pharmacokinetic and pharmacodynamic profiles of Clexane and Lovenox in dogs. (1993) (0)
Generic Versions of Low Molecular Weight Heparin May Not Have the Same Safety-Efficacy Profile as the Branded Low Molecular Weight Heparins In Acute Coronary Syndrome. (2010) (0)
A Generic Version of rFVIIa Is Bioequivalent to the Branded Version of rFVIIa (2022) (0)
Do we have a unified consensus on antithrombotic management of PAD? (2021) (0)
P1403PLASMA OSTEOPONTIN LEVELS DIRECTLY CORRELATE WITH INTACT PARATHYROID HORMONE AND ALKALINE PHOSPHATE LEVELS IN END STAGE RENAL DISEASE (2020) (0)
Aggregates in heparin. (1988) (0)
Argatroban for Percutaneous Coronary Interventions (2008) (0)
Hyperhomocysteinemia in cancer patients with thrombosis is not associated with methylene tetrahydrofolate reductase (MTHFR) gene mutations is down regulated by low molecular weight heparin (LMWHs) treatment (2005) (0)
Gender-Based Differences in Hemostatic Responses. Implications in Effective Anticoagulant Management. (2009) (0)
Oral Throm bosis, Clinical — XI Arterial Thrombosis, Clinical - XII Arterial Thrombosis Treatment (2018) (0)
Biomarker Profiling of Neurovascular Diseases in Patients with Stage 5 Chronic Kidney Disease (2018) (0)
Oversulfated Chondroitin Sulfate Is Not the Sole Contaminant in Recalled Heparin Preparations. (2009) (0)
Biomarker profiling in elderly patients with acute hip fracture: modulation by prophylactic dosage of enoxaparin (2009) (0)
Causality Assessment and Examples of Adverse Drug Reactions (Drug-Induced Liver Injury, Renal, Skin, and Major Adverse Cardiac Events) (2019) (0)
Thrombin Generation Mediators and Markers in Sepsis Associated Coagulapathy (2011) (0)
Upregulation of Microparticles, Tissue Factor, Adhesion Molecules, Nitric Oxide and Adiponectin in End Stage Renal Disease (2015) (0)
PRO-INFLAMMATORY CYTOKINES IN DRUG-FREE SCHIZOPHRENIC PATIENTS (2008) (0)
Von Willebrand Factor and vWF Propeptide are Up‐regulated in Heparin‐Induced Thrombocytopenia (2010) (0)
Proinflammatory Status in Major Depression: Effects of Escitalopram (2010) (0)
Thromboplastin C Supplemented Modified Activated Clotting Time (ACT) is Quite Ideal for Monitoring Direct Thrombin Inhibitors at High Concentrations (2006) (0)
Comparison of the Pharmacokinetic and Pharmacodynamic Behavior of Branded and Generic Enoxaparin in Non-Human Primates (2011) (0)
S100. Elevated Matrix Metaloproteinase 9 in Treatment Resistant Bipolar Depression (2019) (0)
Abstract 18466: Angiopoietin-2 as a Predictive Biomarker of Atrial Fibrillation in Patients With Stage 5 Chronic Kidney Disease (2017) (0)
Increased Anaphylatoxin (C5a) and Bradykinin Levels in Patients with End‐Stage Renal Disease on Maintenance Hemodialysis: Potential Relevance to Heparin Mediated Hemodynamic Responses (2009) (0)
Tissue Factor Mediated Activation of Prothrombin Complex Concentrates and its Inhibition by Antithrombin Drugs. (2004) (0)
How to manage coagulopathy in Klippel–Trenaunay syndrome? (2019) (0)
Evaluation of the Antithrombotic and Hemorrhagic Effects of a Novel Ultra Low Molecular Weight Heparin (ULMWH) (2012) (0)
Semuloparin Efficiently Inhibits Thrombin Generation Triggered by Pancreas Adenocarcinoma Cells BXPC3. Distinct Roles of Anti-XA and Anti-IIA Activity (2012) (0)
CONTRAST MEDIA (CM) INHIBITION OF INDUCED THROMBOSIS IN RABBITS (1983) (0)
Biomarkers of Inflammation and Infection in Sepsis Associated Disseminated Intravascular Coagulation and Their Prognostic Role (2016) (0)
Pathogenesis of heparin contaminant mediated vascular and hemostatic responses in animal models (2009) (0)
Newer pharmacologic approaches targeting receptors and genes (2007) (0)
Differential Inhibition of Arachidonic Acid Mediated Aggregation of Platelets by Branded and Generic Argatroban Preparations (2010) (0)
Increased Levels of Anaphylatoxin (C5a) and Bradykinin in End-Stage Renal Disease Patients on Maintenance Hemodialysis. Potential Relevance to Heparin Mediated Hemodynamic Responses (2008) (0)
Elevation of soluble thrombomodulin in acute coronary syndrome and its modulation by low molecular weight heparins (2002) (0)
Comparative Studies on the Interaction of Heparins from Various Origins with Heparin Cofactor II and Antithrombin (2022) (0)
Upregulation of Inflammatory Mediators In End-Stage Renal Disease as Measured Via Biochip Array Technology (2010) (0)
A Generic Recombinant Factor VIIa is Comparable to the Branded Novoseven in In‐Vitro and Pharmacokinetic Studies in Primates (2019) (0)
Von Willebrand Factor Cleaving Protease (ADAMTS-13) Antigen Levels Are Decreased in Patients with Heparin-Induced Thrombocytopenia. (2005) (0)
Author and Subject Index (2003) (0)
Blood Coagulation and Anticoagulant Drugs (2003) (0)
ASPIRIN DESENSITIZATION OF THROMBIN RECEPTOR‐MEDIATED ACTIVATION OF PLATELETS: DIGNOSTIC AND CLINICAL IMPLICATIONS.: 1 (1998) (0)
Cross‐Reactivity of Rabbit Anti‐Bovine Thrombin IgGs with a Human Plasma Derived Thrombin Preparation (Evithrom™) (2010) (0)
Betaine, a Novel Antithrombotic Agent for Effective Management of Peripheral Arterial Occlusive Diseases (2006) (0)
Oral Anti-Factor Xa and Factor IIa Agent Mediated Inhibition Of Tissue-Factor Mediated Generation Of Thrombin In Prothrombin Complex Concentrates (2013) (0)
Procoagulant Phospholipid Dependent Clotting Time: A New Tool for the Identification of Multiple Myeloma Patients at Risk Poor Treatment Response (2017) (0)
Cardiovascular complications in CKD 5D (1) (2011) (0)
Validation Studies on Coagulation Laboratory Assays Useful for Assessing the Plasma Levels of Apixaban (2014) (0)
Oversulfated Chondroitin Sulfate Increases the Antithrombotic and Bleeding Effects of Heparin (2009) (0)
Higher Prevalence of Heparin-Induced Thrombocytopenia Antibodies in Asian Indian Population: Is This Due to Contaminated Heparin? (2009) (0)
PREDICTORS OF ANTICOAGULATION COMPLIANCE IN PATIENTS WITH PULMONARY EMBOLISM AFTER HOSPITAL ADMISSION (2021) (0)
Hyperhomocysteinemia in cancer patients with thrombosis is independent of methylene tetrahydrofolate reductase gene mutation. (2004) (0)
Comparative Studies on Branded Dalteparin with Two Generic Versions: Hepagumin and Fluzepamin (2010) (0)
NOVEL BIOMARKERS FOR RISK STRATIFICATION IN ACUTE PULMONARY EMBOLISM (2019) (0)
Considerations in the standardization of the functional and immunologic assays for human procarboxypeptidase U. Diagnostic implications (2003) (0)
Contents, Vol. 52, 1989 (1989) (0)
STUDIES ON THE PERFORMANCE CHARACTERISTICS OF TWO ELISA‐BASED METHODS FOR THE QUANTITATION OF SOLUBLE THROMBOMODULIN IN PLASMA.: 3 (1998) (0)
POS-790 CIRCULATING HEPARIN AND ITS RELEVANCE TO THROMBIN GENERATION PROFILE IN ESRD PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS (2021) (0)
Characterization of the Antithrombotic Fingerprint of the Branded and Copies of the Low-Molecular-Weight Enoxaparin Using Thrombin Generation Assay (2015) (0)
Comparative studies of purified poloxamer 188 using clot‐based and viscoelastic measurements of coagulation (833.5) (2014) (0)
S94. Tumor Necrosis Factor Alpha in Major Depressive Disorder: Effects of Anti-Depressant Treatments (2019) (0)
Measurements of Prothrombin Fragment 1.2 In Urine and Blood to Assess Hypercoagulability In Preeclampsia (2010) (0)
Personalized Medicine for Coagulopathies (2017) (0)
Increased Levels of Cortisol in Patients Undergoing Total Joint Arthroplasty may be Associated with Stress and Inflammatory Processes (2020) (0)
Altered Coagulation Parameters and D‐Dimer Measurements in Sepsis are useful in Scoring the Risk Stratification (2020) (0)
Abstract 16854: End-Stage Renal Disease Associated With Metabolic Syndrome: A Study of Biomarkers Relevant to Cardiovascular Risk (2014) (0)
CT DETECTION OF HEMORRHAGIC AND THROMBOTIC DISORDERS IN THE TORSO (1981) (0)
Upregulation of Microparticles and CD40 Ligand in Antiphospholipid Syndrome: Potential Implication in Inflammatory Responses and Thrombosis. (2007) (0)
POS-403 VARIATIONS IN THE THROMBIN GENERATION PROFILE AND CLOTTING FACTOR LEVELS IN THE PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS (2021) (0)
ENDOGENOUS ACTIVATION OF THROMBIN GENERATION IN ATRIAL FIBRILLATION AND ITS RELEVANCE TO PROTHROMBIN FRAGMENT 1.2 AND D-DIMER (2021) (0)
Abstract 15792: Effect of Dabigatran and Rivaroxiban on Thrombomodulin Mediated Activation of Protein C and Thrombin Activated Fibrinolysis Inhibitor (TAFI) (2012) (0)
1123 POSTER Enoxaparin Down Regulates Inflammatory and Thrombotic Mediators in Cancer Patients as Studied Using Protein and Biochip Array Approaches (2011) (0)
Enhanced Inflammatory response in cancer patients with end stage renal disease. Implications in thrombotic risk stratification (2005) (0)
Abstract 14049: Correlation of Cellular Indices and D-dimer/fibrinogen Ratio to Gender Differences in 6-minute Walk Test Distance in Patients Presenting With Acute Pulmonary Embolism (2020) (0)
Effect of Heparin:PMX60056 Complexes on Platelet Aggregation Induced by ADP or HIT Antibody (2010) (0)
SP117ENDOCAN AS A BIOMARKER OF ENDOTHELIAL FUNCTION IN END STAGE RENAL DISEASE (2015) (0)
Glycosaminoglycans for the treatment of emotional dysfunctions (2004) (0)
Upregulation of monocyte chemotactic protein-1 and CD40 ligand in cancer patients and their modulation by subcutaneous enoxaparin-results from the ONCENOX study. (2004) (0)
Reply to Dr. Nowak’s Letter (1992) (0)
Pharmacokinetics and pharmacodynamics of recombinant hirudins (1991) (0)
Collagen Remodeling Proteins, Inflammatory Biomarkers and FABP Regulation in Understanding the Pathogenesis of Atrial Fibrillation (2022) (0)
Pharmacopeia Potency Equated Sulodexide Produces Comparable Anticoagulation as Studied in Whole Blood (2020) (0)
Antiplatelet Drugs in the Management of Cardiovascular Indications (2014) (0)
Anticoagulant response variability in generic versions of argatroban. Dosing Implications (2011) (0)
Molecular Heterogeneity in Recombinant Erythropoietin Using Surface Enhanced Laser Induced Desorption Ionization (SELDI). Clinical Implications. (2005) (0)
Differentiation of low molecular weight heparins as studied by molecular weight profile and heparinase-I depolymerization: pharmacologic implications (2007) (0)
DIFFERENTIAL EFFECTS OF CLIVARIN AND HEPARIN IN HIP AND KNEE SURGERY FOR THE GENERATION OF ANTI‐HEPARIN‐PF4 ANTIBODIES.: 100 (2001) (0)
Fibrinopeptide-A generation inhibition by anti-Xa drugs and its correlation with activated clotting time (2003) (0)
AB3-4: Pathogenesis of atrial fibrillation and hypercoagulability: Potential role of inflammatory response (2006) (0)
Hydrolysis of heparinase I to synthetic heparin-pentasaccharide and effect on its anti-factor Xa activity (2001) (0)
Thrombomodulin Inhibits Tissue factor Mediated Thrombin Generation in blood and Prothrombin Complex Concentrates (2015) (0)
Reversal of the Thrombin Generation Inhibitory Effect of Apixaban, Betrixaban, Edoxaban and Rivaroxaban by Andexanet Alpha may be Associated with Increased Thrombogenesis (2019) (0)
Anticoagulant Effects of a Synthetic Anti-Factor Xa Inhibitor ( DX-9065 a ) : Implications for Interventional Use (2006) (0)
Biological activities of two ultra‐low molecular weight heparins, semuloparin and bemiparin, reveal that a common potency standard is inappropriate (2011) (0)
Prevalence of Anti-Heparin Platelet Factor 4 Antibodies in Patients with Disseminated Intravascular Coagulation. (2009) (0)
Compositional variations in porcine mucosal heparins used for the production of low molecular weight heparins. Impact on generic low molecular weight heparin development (2007) (0)
Fibrinolytic Dysregulation Contributes to the Hypercoagulable State in Pulmonary Embolism Patients (2021) (0)
Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study (2021) (0)
Differential inhibition of tissue factor mediated activation of thrombin generation by Dabigatran, Apixaban, Rivaroxaban and Otamaxaban. Pharmacologic implications (2013) (0)
Activation of Prekallikrein by Contaminated Heparins, Isolated Contaminant and Related Hypersulfated Chondroitin Sulfate Preparations: Pharmacologic Implications (2009) (0)
Comparative studies on the anticoagulant and antiprotease activity of bovine, ovine and porcine heparins. (2016) (0)
RECOMBINANT THROMBOMODULIN DOES NOT CROSS REACT WITH ANTI-HEPARIN PLATELET FACTOR 4 ANTIBODIES. POTENTIAL IMPLICATION FOR ANTICOAGULATION OF HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS (2007) (0)
MON-315 PLASMA OSTEOPONTIN LEVELS DIRECTLY CORRELATE WITH INTACT PARATHYROID HORMONE AND ALKALINE PHOSPHATE LEVELS IN END STAGE RENAL DISEASE (2019) (0)
Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum (2018) (0)
Synthetic Peptide Assays For Monitoring The Defects Of Extrinsic And Intrinsic Pathways Of Coagulation: Selection Of A Suitable Substrate (1981) (0)
SEVERITY RATHER THAN MECHANISM OF INJURY IMPACTS HEMOSTASIS IN BURNS/TRAUMA.: 97 (1995) (0)
COMPARATIVE STUDY ON THE ANTICOAGULANT EFFECTS OF UNFRACTIONATED AND LOW MOLECULAR WEIGHT HEPARINS, LOWER LOW MOLECULAR WEIGHT HEPARINS AND PENTASACCAHRIDE AS MEASURED BY WHOLE BLOOD ACT, ANTI-XA AND A NEWLY DEVELOPED PROTHROMBINASE INDUCED CLOTTING TIME (2007) (0)
Perspectives in hemostasis : selected proceedings of the first and second symposia held May 11, 1979 and May 22-25, 1980 at Loyola University Medical Center, Maywood, Illinois USA (1981) (0)
Title Page / Table of Contents, Vol. 21, Supplement 1, 1991 (1991) (0)
[Lipid-lowering drugs]. (1988) (0)
Title Page / Table of Contents, Vol. 21, Supplement 1, 1991 (1991) (0)
Differentiation of the anti‐coagulant effects of Activated Protein C and Recombinant Thrombomodulin as studied in whole blood and retrieved plasma (2018) (0)
COLLAGEN TURNOVER BIOMARKERS IN ATRIAL FIBRILLATION AND THEIR USE IN CLINICAL MANAGEMENT AND THE STUDY OF INFLAMMATORY PATHOGENESIS (2021) (0)
Non-Pathogenic Anti-Heparin/PF4 Antibodies Generated by Low Molecular Weight Heparins Mediate Procoagulant Effects. (2010) (0)
Contents, Vol. 22, 1992 (2004) (0)
Bio‐equivalence of Potency Adjusted Approved Heparin Solutions Compared to a Newly Developed Heparin Solution (2022) (0)
BIOMARKER PROFILING IN PULMONARY EMBOLISM PATIENTS WITH PRE-EXISTING VS NEW-ONSET ATRIAL FIBRILLATION (2020) (0)
Plasma procarboxypeptidase U is up-regulated in patients undergoing percutaneous intervention: effects of anticoagulant dosage of low molecular weight heparins (2003) (0)
Heparin-derived oligosaccharides as potential therapeutic agents in senile dementia and stroke (2005) (0)
Comparison of Seven Generic Enoxaparins with Lovenox® on In Vitro Cross-Reactivity with Antibodies From Heparin Induced Thrombocytopenia. (2010) (0)
Assessment of thrombogenicity of activated and non-activated prothrombin concentrates in a rat model. (1986) (0)
Comparative Anticoagulant Effects of Suledoxide and Enoxaparin in Citrated Whole Blood (2008) (0)
Pitfalls in Warfarin Therapy (2006) (0)
In Vitro Characterization Of Low Molecular Weight Fractions Of Heparin (1981) (0)
Selective Serotonin Reuptake Inhibitors Influence Agonist‐Induced Platelet Aggregation. Preliminary Results from Co‐morbidity of Depression and Cardiovascular Disease Study (2008) (0)
BRIEF COMMUNICATION DIRECT INHIBITION OF PROTEIN Ca BY SITE DIRECTED THROMBIN INHIBITORS: IMPLICATIONS IN ANTICOAGULANT AND THROMBOLYTIC THERAPY. (1995) (0)
Non‐antithrombin affinity Semuloparin and it's component oligosaccharides release endogenous TFPI in a molecular weight dependent fashion (2012) (0)
Biomarker profiling of rat plasma from different gender and age groups using SELDI‐TOF MS (2006) (0)
Comparative Studies on the Oral Anticoagulant Activities of Orally Active Anti‐Xa and Anti‐IIa Agents in Whole Blood and Plasma and their Neutralization by FEIBA (2019) (0)
Combined Vaccination Approaches for COVID-19. Will These Improve the Efficacy Spectrum? (2021) (0)
A Tribute to Professor Hans Klaus Breddin (2008) (0)
Abstract 13268: Differential Thrombin Generation by Newer Anti-Xa and Anti-IIa Drugs in Prothrombin Complex: Relevance to Endogenous Modulation of Thrombogenesis (2011) (0)
USP Standardized Mixtures of Bovine, Ovine and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single Sourced Heparins and May be Interchangeable, (2021) (0)
Functional Protection of Platelets By Tri-Block Polymer (Poloxamer-188 ) As Studied in Agonist Induced Platelet Aggregation Systems (2015) (0)
Molecular profiles of recent partially depolymerized heparin calibrants A comparison (1995) (0)
Pharmacokinetic and Pharmacodynamic Profiles of Potency‐Adjusted Doses of Bovine, Ovine and Porcine Heparin are Comparable in a Primates Model (2019) (0)
The classical vs nonclassical NSAIDs (2006) (0)
Urgent Interventional Therapies: Kipshidze/Urgent Interventional Therapies (2014) (0)
OF NORTH AMERICA Controversies and Unresolved Issues in Antiphospholipid Syndrome Pathogenesis and Management (0)
Cardiolipin Antibody: A Potential Biomarker for Depression (2022) (0)
SP272PROFILING OF NEUROVASCULAR DISEASES IN PATIENTS WITH STAGE 5 CHRONIC KIDNEY DISEASE USING SPECIFIC BIOMARKER PROFILING (2018) (0)
Amplified Thrombo-Inflammatory Biomarkers in Pulmonary Embolism with Augmented Responses in Von-Willebrand Factor, Microparticles and Interleukin-6 in Patients with Cancer (2022) (0)
Problematic Aspects Of Synthetic Peptide Substrate Assays For Coagulation Parameters (1981) (0)
Interrelationship Between Inflammatory Biomarkers and Collagen Remodeling Proteins in Atrial Fibrillation (2023) (0)
TIMING OF FACTOR XA INHIBITORS AFTER CATHETER-DIRECTED THROMBOLYSIS IN PATIENTS WITH ACUTE PULMONARY EMBOLISM (2020) (0)
Reduced Fibrinolysis in the Hepatic Venous Occlusive Disease: Effect of Defibrotide on Plasmin Activity. (2007) (0)
Metabolic syndrome marker profile in patients with hepatocellular carcinoma HCC. (2015) (0)
Comparative Studies on a Branded Recombinant Factor VIIa and Its Generic Version to Demonstrate Bioequivalence (2017) (0)
Effect of Recombinant Lubricin on Coagulation Parameters in Human Blood (2015) (0)
Biological Activities and Effects on the Platelet Aggregation of a Structurally Defined Curdlan Sulfate (1996) (0)
the role of sulodexIde In chronIc venous InsuffIcIency (2014) (0)
Association of Inflammatory and Hemostatic Biomarkers with Inflammasomes in Septic Patients at Risk for Development of Coagulopathy (2019) (0)
RELATIVE ANTICOAGULANT AND ANTITHROMBOTIC EFFECTS OF HEPARIN AND LOW MOLECULAR WEIGHT HEPARINS IN HUMAN AND FELINE BLOOD PLASMA. POTENTIAL THERAPEUTIC IMPLICATIONS (2007) (0)
Facilitation of urokinase‐mediated fibrinolysis by MST‐188 (833.7) (2014) (0)
Pharmacokinetics of Defibrotide in Non‐Human Primates is Dose Dependent. (2008) (0)
A Polydeoxynucleotide Derived Drug Defibrotide Inhibits Nucleosome Generation in Whole Blood. Implications in the Management of VOD (2017) (0)
Increased Antithrombotic and Bleeding Effects of Contaminated Heparins; Hematological Implications (2008) (0)
A Comparison of GMP Manufactured Ovine Mucosal Enoxaparin and Branded Porcine Enoxaparin (2019) (0)
Differential Digestion of Different LMWHs by Heparinase-I and Heparinase-II: Drug Developmental Implications. (2004) (0)
Enoxaparin (E) and Warfarin (W) Differentially Regulate Tissue Factor (TF), Tissue Factor Pathway Inhibitor (TFPI), Nitric Oxide (NO), and Thrombin Activatable Fibrinolytic Inhibitor (TAFI) in Cancer Patients with Thrombosis (2006) (0)
Trypsin Mediated Activation of Thrombin Activatable Fibrinolytic Inhibitor (Carboxypeptidase U): Potential Clinical Implications. (2006) (0)
THE EFFECTS OF HYPERTHERMIC RESUSCITATIVE FLUID ON COAGULATION IN HYPOTHERMIC CANINES (1998) (0)
Persistant Inhibition of Thrombin Generation After Intravenous Administration of Enoxaparin in Primates. (2009) (0)
Assay Dependent Reversal of the Oral and Parenteral Anti-Xa Agents By Andexanet Alfa (2020) (0)
Potential Hemorrhagic Effects of K5‐Derivatives of Bacterial Origin : Practical Implications to Develop New Class of Heparin‐like Drugs (2006) (0)
Use of Thrombin Generation Assay As Tool for the Evaluation of the Antithrombotic Samenesse of Enoxaparine Copies (2014) (0)
Dilute Russell's Viper Venom Clotting Time (DRVVT) is Useful for the Routine Monitoring of Newer Non‐Vitamin K Anticoagulants (2015) (0)
Cross-Reactivity of Rabbit Anti-Bovine Prothrombin/Thrombin IgGs With Bovine Factor V/Va-Related Antigens (2010) (0)
Clinical and Laboratory Validation of the 2nd International Standard of Low Molecular Weight Heparin (IS 2003-01/608) in the Anti-Xa, Anti-LIA Heptest and Prothrombinase Induced Clotting (PiCT) Tests. (2005) (0)
Proteomic Analysis of the Keraotoconus Cornea by ProteinChip® Array (2009) (0)
A simulated post-angioplasty low molecular weight heparin schedule in a non-human primate model. (1993) (0)
Management of deep vein thrombosis. (2007) (0)
Comparative Studies on the Molecular and Functional Profile of Sheep Mucosal Derived Enoxaparin (2015) (0)
Fibrinolytic compromise by simultaneous administration of synthetic and recombinant antithrombotic agents (1994) (0)
Circulating Biomarker Levels in Patients With Stage 5 Chronic Kidney Disease With Respect to Neurovascular Diseases (2018) (0)
ENDOGENOUS THROMBIN GENERATION POTENTIAL IN PATIENTS WITH PULMONARY EMBOLISM AND ITS RELEVANCE TO THROMBOTIC AND INFLAMMATORY BIOMARKERS (2020) (0)
Increased Nitrotyrosine Levels Observed in Acute Myocardial Infarcation. Early Diagnostic Implication (2006) (0)
Enoxaparin Produces Sustained Antithrombotic Effects in Comparison to Fondaparinux and Rivaroxaban: Clinical Implications. (2009) (0)
International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treated and Those with Disseminated Intravascular Coagulation (2016) (0)
Chapter-10 Monitoring the New Antithrombotic Drugs (2006) (0)
Validation of the Low-Molecular-Weight Heparin Standard (1989) (0)
Intravascular Coagulation Dysregulation of Inflammatory and Hemostatic Markers in Sepsis and Suspected Disseminated (2013) (0)
Regional and Systemic Prothrombotic Biomarkers in Varicose Vein Patients and Healthy Controls. (2014) (0)
New oral anticoagulant in atrial fibrillation: are they comparable? (2012) (0)
200. Vascular endothelial growth factor: A biomarker of depression may predict antidepressant response (2011) (0)
Efficacy of recombinant hirudin as ah anticoagulant in a dog cardiopulmonary bypass model (1990) (0)
Cross Reactivity of Rabbit Anti-Recothrom (Human Recombinant Thrombin) Antibodies with Molecular Variants of Human Thrombin, and Various Bovine Thrombin Preparations (2010) (0)
Comparative Studies on the USP Reference Standard Over‐Sulfated Chondroitin Sulfate and Two Semi‐synthetic Over‐Sulfated Chondroitin Sulfate Preparations (2010) (0)
Abstract 19152: Increased Extracellular Nucleosome Levels, Biomarkers of Cell Death, in Atrial Fibrillation Patients Compared to the Normal Population (2016) (0)
Frequency of Anti-Erythropoietin Antibodies in Patients with End Stage Renal Disease Treated with Recombinant Erythropoietin. (2005) (0)
S95. Plasma MCP-1 Levels in Bipolar Depression During Cyclooxygenase-2 Inhibitor Combination Treatment (2019) (0)
Application of Rotational Thromboelastometry in Patients with Acute Promyelocytic Leukemia (2022) (0)
Assessment of HIT Antibody Complex in Hip Fracture Patients Receiving Enoxaparin or Unfractionated Heparin (2011) (0)
Defibrotide Interactions with Anticoagulant Drugs. Developmental Implications. (2008) (0)
Usefulness of Dilute Russell’s Viper Venom Clotting Time (DRVVT) for the Routine Monitoring of New Oral Anticoagulants (2014) (0)
The Approach of Thromboelastography in the Monitoring of New Synthetic Antithrombotic Agents, GL-522 and GL-2021 (1995) (0)
Catheter-Based Local Delivery of Therapeutics to the Lungs for Severe or Critically Ill Patients with COVID-19 (2021) (0)
Upregulation of Matrix Degrading Enzymes and Lubricin in the Pathogenesis of Joint Disease Requiring Arthroplasty (2016) (0)
Differential binding of low molecular weight heparins with antithrombin and platelet factor 4 as measured by surface enhanced laser desorption ionization (SELDI) (2012) (0)
Comparative studies on the effect of newer oral anticoagulants on platelet aggregation. Pharmacological and developmental implications (2012) (0)
Does Contaminated Heparin Lead to a Higher Prevalence of HIT Antibodies? (2009) (0)
Fractionation Of Heparin By Human PF-4 Affinity Resin (1981) (0)
Bioavailability of oversulfated chondroitin sulfate in rats. Pharmacological implications in contaminated heparins (2009) (0)
Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors—An In Vitro Study (2021) (0)
Differential Neutralization of Unfractionated Heparin, Enoxaparin and Fondaparinux by Andexanet Alpha (2019) (0)
DEVELOPMENT OF A RAPID HPLC METHOD FOR THE SIMULTANEOUS QUANTITATION OF ARGATROBAN AND ITS METABOLITE: APPLICATIONS IN THE PHARMACOKINETIC STUDIES IN SHOCK PATIENTS.: 41 (1998) (0)
Increased Procalcitonin Levels in End Stage Renal Disease and Chronic Kidney Disease as An Indicator of Inflammatory Activation (2008) (0)
Correction to Analysis of 3-O-Sulfated Heparan Sulfate Using Isotopically Labeled Oligosaccharide Calibrants. (2022) (0)
In Memoriam (2009) (0)
Molecular Mimicry in the Adulteration of Heparins. Chemical Basis for the Development of Oversulfated Chondroitin Sulfate and Related Contaminants (2011) (0)
Relative neutralization of unfractionated heparin and various Enoxaparins by platelet factor 4 in platelet rich plasma. Therapeutic implications (2013) (0)
PULMONARY EMBOLISM RESPONSE TEAM IMPLEMENTATION IMPROVES AWARENESS AND EDUCATION AMONG THE HOUSE STAFF (2019) (0)
Malignant Clonal Cell Proliferation in Multiple Myeloma and the Hypercoagulable State (2020) (0)
SP089END-STAGE RENAL DISEASE ASSOCIATED WITH METABOLIC SYNDROME: A STUDY OF BIOMARKERS UTILIZING BIOCHIP ARRAY PROFILING METHODS (2015) (0)
Comparative Anticoagulant Effects of Parenteral Sulodexide as Measured by Activated Clotting Time. Relevance to Dosing in Various Indications (2020) (0)
P1077PERSISTENCE OF CIRCULATING RESIDUAL HEPARIN IN ESRD PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS (2020) (0)
MACHINE LEARNING-BASED PREDICTION OF 30-DAY ALL-CAUSE MORTALITY IN PATIENTS HOSPITALIZED WITH ACUTE PULMONARY EMBOLISM (2020) (0)
Activation of fibrinolysis in patients with mechanical heart devices (1990) (0)
Molecular Profiling of Generic Versions of the Low Molecular Weight Heparin Enoxaparin and Their Digestion by Heparinase‐I. (2008) (0)
AMPLIFICATION OF INFLAMMATORY AND HEMOSTATIC DYSREGULATION RESPONSES IN ATRIAL FIBRILLATION PATIENTS WITH END-STAGE RENAL DISEASE (2020) (0)
F175. Cyclooxygenase-2 Inhibitor Combination Treatment Reduces Plasma C-Reative Protein Levels in Bipolar Depression (2018) (0)
Comparative Studies on the HIT Antibody Mediated Platelet Aggregation / Serotonin Release by Synthetic Pentasaccharide and Two Chemoenzymatically Synthesized Heptasaccharides (2011) (0)
The Application Of Computed Tomography In The Diagnosis And Management Of Dissecting Aortic Aneurysms (1981) (0)
9140 POSTER Procoagulant and Inflammatory Mediators in Small Cell Lung Carcinoma – Potential Role in Thromboembolic Complications (2011) (0)
Differential Interaction of Anti‐heparin Platelet Factor 4 Antibodies with Branded and Generic Versions of Low Molecular Weight Heparins. Pathophysiologic and Bioequivalence Implications. (2008) (0)
Differential Modulation of Plasminogen Activator Mediated Thrombolysis By Recombinant Thrombomodulin and Activated Protein C (2017) (0)
Trypsin Mediates the Activation of Thrombin Activatable Fibrinolytic Inhibitor: Potential Clinical Implications (2007) (0)
Oversulfated Chondroitin Sulfate Does Not Cause Augmentation in HIT Antibody Mediated Heparin-Induced Platelet Aggregation (HIPA). (2009) (0)
HEMOSTATIC DISORDERS IN CHILDREN WITH CYANOTIC CONGENITAL HEART DISEASE (CCHD) (1984) (0)
DIFFERENTIAL MECHANISMS OF ANTICOAGULANT ACTIONS OF ANGIOMAX AND HEPARIN: POTENTIAL PHARMACOLOGIC IMPLICATIONS (2006) (0)
An Ex Vivo Analysis of Thrombin Generation and Thromboelastometry in Patients Undergoing Treatment with Rivaroxaban Demonstrates Sustained Anticoagulant Effect and High Inter-Individual Variability (2017) (0)
Comparative Studies on Six Unfractionated Heparin Batches from China (2010) (0)
Biochemical and Pharmacologic Rationale for Synthetic Heparin Polysaccharides (2005) (0)
Fibrinolytic Status and Risk of Death After Acute Pulmonary Embolism (2023) (0)
Nitric Oxide and Asymmetric Dimethylarginine Levels in Malignancy Associated Thrombosis and Their Modulation by Anticoagulants (2006) (0)
Platelet aggregation associated with ethanol intoxication (1989) (0)
Up-regulation of inflammatory and thrombotic mediators in lung cancer and their modulation by oral anticoagulantion (2007) (0)
Potency Adjustment of Unfractionated Heparins to Harmonize the USP and WHO Standardization. Impact on Anticoagulant Practice in the US (2010) (0)
507. Relationship Between Vascular Endothelial Growth Factor (VEGF) and Peripheral Inflammation Markers in Treatment-Resistant Bipolar Depression Disorder (TRBDD) (2023) (0)
Dysregulation of Inflammatory and Hemostatic Markers In Disseminated Intravascular Coagulation. (2010) (0)
Differential down Regulation of Inflammatory Cytokines, CRP, CD 40-L, MCP-1 and NO Levels in Malignancy Associated Thrombosis by Extended Treatment of Enoxaparin and Warfarin. (2004) (0)
Our thanks to reviewers in 2011 (2011) (0)
Comparison of Functional Methods with Absolute Quantitation of Heparin Levels in Clinical Samples as measured by Heparin Red Assay (2021) (0)
Neutrophil to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR) and Risk of Thromboembolism in Patients with Lymphoma (2019) (0)
Thrombosis and fibrinolysis: Current clinical and therapeutic aspects: Preface (1991) (0)
Fibrinolytic and hemodynamic compromise by adjunct therapeutic agents used in thrombolysis. Comparative studies with recombinant tissue factor pathway inhibitor (1994) (0)
Relative Neutralization of Heparin from Different Origins by Protamine, Polybrene, Platelet Factor 4, and synthetic heparin antagonist PMX (2018) (0)
Upregulation of procalcitonin in cancer patients with venous thrombosis is independent of sepsis (2008) (0)
To what extent should anticoagulation therapy be considered for venous malformations? (2019) (0)
An Update on Antiphospholipid Syndrome (2006) (0)
Intracranial Radiation-Induced Meningiomas (2015) (0)
Whole blood anticoagulant effects of Sulodexide as measured by activated clotting time and their neutralization by Protamine sulfate (2021) (0)
Clinical evaluation of a new functional, plasma-based assay for the detection of Factor V Leiden - the pefalkit (R) APC-R Factor v Leiden assay. (2004) (0)
Interactions of Antithrombin, Anti‐Xa, and Anti‐Platelet Agents, as Evaluated by Clot‐Based and Platelet Aggregation Assays (2006) (0)
Antithrombotic Properties Of Low Molecular Weight Heparin Fractions From Porcine Mucosal Heparin (1981) (0)
New Oral Anticoagulants (2012) (0)
Abstract 10768: Use of Cellular Indices to Predict All-Cause Mortality Outcomes in Patients with Pulmonary Embolism (2021) (0)
Comparative analysis of inflammatory cytokines and growth factors in young and old aged normal individuals (2017) (0)
Prevalence of Heparin Induced Thrombocytopenia Antibodies During the Period 2004–2011. Relevance to Heparin Contaminants (2011) (0)
Biomarkers, inflammation, and thrombosis in Hepatocellular Carcinoma (2021) (0)
Potency Adjusted Blended Heparin of Bovine, Ovine, and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single-Sourced Porcine Heparin (2023) (0)
Profiling of inflammatory biomarkers in synovial fluid from patients undergoing primary total joint arthroplasty (2017) (0)
Relative Purity of Different Bovine Thrombin Preparations (2009) (0)
123: Is premature labor a state of platelet activation? (2007) (0)
Hirudin does not prevent platelet activation in heparin induced thrombocytopenic syndromes (1998) (0)
Abstract 16899: Neutralization of Bleeding Induced by Direct Factor Xa and Thrombin Inhibitors by Prothrombin Complex Concentrates Alone and in Combination with Antifibrinolytic Agents (2014) (0)
Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication (2020) (0)
Will warfarin become obsolete (2012) (0)
Synthetic Anti-Xa Drugs Can Be Used for Parenteral Anticoagulation but Not Fondaparinux. (2004) (0)
Serine Protease Inhibitor Dependence of Heparin Mediated Inhibition of Thrombin Activatable Fibrinolytic Inhibitor (2007) (0)
Coagulation and Circulating Heparin Profile in Patients with End‐Stage Renal Disease Undergoing Maintenance Hemodialysis (2019) (0)
In Vivo Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by a Novel Salicylamide Derivative. (2008) (0)
Elevated Thrombin Generation Biomarkers and Their Relevance with Decreased Thrombin Generation Potential in Patients with Pulmonary Embolism (2022) (0)
Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants (2013) (0)
Impact of Contaminant Heterogeneity on Anticoagulation and Adverse Reactions Associated with Recalled Heparin (2009) (0)
Serine Protease Generation by Oversulfated Chondroitin Sulfate and Contaminants in Heparin: Clinical Implications (2011) (0)
3075 POSTER An Ultra Low Molecular Weight Heparin LMWH (Semuloparin) Blunts the Procoagulant Effect of Microparticles. the Rationale Behind Its Use in the Management of Thrombosis in Cancer Patients (2011) (0)
Differential effects of unfractionated heparin and a low molecular weight heparin on anti-thrombin activity during the treatment of deep vein thrombosis (2003) (0)
Development of Non-Anticoagulant Derivatives of Biotechnology Derived Sulfaminoheparosan Derivatives to Investigate the Non-Anticoagulant Effects of these Agents. (2004) (0)
Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism (2023) (0)
Inflammatory and Procoagulant Cytokine Levels During Pregnancy As Predictors of Adverse Complications (2011) (0)
Methodologic Variations in the Determinations of Anti-Platelet Factor 4-Heparin Antibodies in Patients Suspected of Having Heparin Induced Thrombocytopenia: Diagnostic and Prognostic Implications. (2007) (0)
SUBMASSIVE PULMONARY EMBOLISM: ARE WE FALSELY REASSURED BY NORMOTENSION? (2019) (0)
Abstract 501: Up-Regulation of Inflammatory Mediators and Markers of Metabolic Deraignment in ESRD as Studied by Biochip Array Analysis (2014) (0)
Discordance between the neutralization profile of apixaban, betrixaban, edoxaban and rivaroxaban in the clotting assays and anti‐Xa measurements (2020) (0)
Biochip Array Profiling of Neuron Specific Enolase, Neutrophil Gelatinase‐associated Lipocalin, Soluble Tumor Necrosis Factor Receptor I, D‐Dimer, Thrombomodulin, and C‐reactive Protein in End Stage Renal Disease (2010) (0)
Recent developments in antithrombotic therapy (1995) (0)
Upregulation of Inflammatory Mediators in Lung Cancer and Their Modulation by Oral Anticoagulant Therapy (2007) (0)
Prevention of Postthrombotic Syndrome (2013) (0)
Recent development in antithrombotic therapy. (1989) (0)
Meeting Highlights Cardiovascular & Renal: 7th IBC Annual Conference on Anticoagulant, Antithrombotic and Thrombolytic Therapy Boston, MA, USA 21-14 October 1996 (1996) (0)
Anti-Heparin and Platelet Aggregation Activities of Polyamino Acids (1977) (0)
The effect of tissue factor pathway inhibitor release and interactions with growth factors on the antitumor effects of ultra low molecular weight heparin semuloparin. (2012) (0)
DYSREGULATION OF RENIN AND COLLAGEN REMODELING IN ATRIAL FIBRILLATION (2019) (0)
Upregulation of surrogate markers of inflammation and thrombogenesis in ESRD patients: pathophysiologic and therapeutic implications (2007) (0)
Response Variation in Patients Treated With Clopidogrel (2010) (0)
C-18 | Novel CT-derived Parameter for Risk Stratification in Patients with Acute Pulmonary Embolism (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jawed Fareed?

Jawed Fareed is affiliated with the following schools:

Jawed Fareed's Academic­Influence.com Rankings

Jawed Fareed's Degrees

Why Is Jawed Fareed Influential?

Jawed Fareed's Published Works

Published Works

What Schools Are Affiliated With Jawed Fareed?

Jawed Fareed's AcademicInfluence.com Rankings